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                                                            SUMMARY 
 
Purpose: To evaluate the safety and efficacy of intravesical instillation of a non-viral 
vector encoding TNF-α in an orthotopic bladder cancer model. 
Materials and Methods:  The murine TNF-α cDNA was cloned into vector 
pBud.CE4.1. A murine bladder cancer cell line MB49 was transfected by pBud-TNF-α 
using cationic liposome DOTAP plus methyl-beta-cyclodextrin solubilized cholesterol 
(MBC). TNF-α levels were determined by ELISA. Cell proliferation, cell cycle analysis 
and Annexin V staining were done to examine the effects of pBud-TNF-α. Flow 
cytometric analysis of MHC I, MHC II, ICAM I, B7-1 and Fas molecules were 
performed. In vivo, RT-PCR analysis of TNF-α expression in murine bladder was done. 
MB49 cells were implanted in 24 C57BL/6 mouse bladders. Two days after implantation, 
pBud-TNF-α was instilled in 12 mice with the rest getting the control vector pBud 
intravesically. On day 27, 5 days after the sixth instillation, all bladders were harvested, 
sectioned and examined. The infiltration of immune cells into bladder after TNF-α 
therapy was also investigated.                              
Result: MB49 cells produce 893.7±24.0pg/ml of TNF-α 48 hours after TNF-α 
transfection and their growth was inhibited. Cell cycle analysis and Annexin V staining 
showed MB49 cells were induced to apoptosis after transfection. MHC I, B7-1 and Fas 
expression were also enhanced significantly.  In vivo, three mice died in the control group 
because of excessive bladder tumor burden while 1 died in the pBud-TNF-α treated 
group. Histological study showed that 9 of 12 mice in the control group had bladder 
tumor while only 3 of 12 in the pBud-TNF-α treated group demonstrated bladder cancer. 
 viii
TNF-α mRNA was observed to increase after the first instillation and then return to basal 
level 1 month after the sixth instillation. CD3+ T lymphocytes and NK cells in bladder 
were enhanced after intravesical TNF-α transfection. 
Conclusion: Intravesical instillation of pBud-TNF-α produces a significant anti-tumor 
effect in an orthotopic murine bladder cancer model. Cytokine gene therapy may be 
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CHAPTER ONE                              INTRODUCTION   
 
1.1 BLADDER CANCER 
 
1.1.1 Epidemiology of bladder cancer 
 
Bladder cancer is the fourth most common malignancy in males and the eighth most 
common in women in western countries. It is also the second most common tumor and 
the second most common cause of mortality of all the genitourinary cancers in the United 
States. Each year, over 52,000 new cases are diagnosed with this disease and there are 
more than 12,000 deaths in United States (Lamm et al., 1995). In many Asia countries, 
bladder cancer is the most common urological cancer. It accounts for 52% of all the 
urological cancer in South Korea (Cheon et al., 2002). In Singapore, it lists ninth amongst 
the most common cancer in males (Chia et al., 1995). Noticeably, the incidence rate of 
bladder cancer had increased remarkably worldwide. In the USA, for example, the 
incidence of bladder cancer has increased by 36% in the last decade (Lamm et al., 2000).  
 
There are many suspected risk factors of bladder cancer including: urinary tract infection 
(Kantor et al., 1984; La Vecchia et al., 1991), Schistosoma haematobium (Badawi et al., 
1995), smoking (Mommsen et al., 1983; Fortuny et al., 1999), artificial sweeteners 
(Miller et al., 1977), hair dye (Yu et al., 2002; Gago-Dominguez et al., 2003), 2-
naphthylamine and benzidine (Piolatto et al., 1991; Shinka et al., 1991). 
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1.1.2 Pathology of bladder cancer 
 
More than 90% of bladder cancers are transitional cell carcinoma (TCC). Other types of 
bladder cancer such as squamous cell carcinomas (5%), adenocarcinoma (1%), primary 
lymphoma, sarcoma, rhabdomyosarcoma and leiomyosarcoma account for less than 10% 
of the total cases.   Seventy to 80% of TCC appears as papillary tumors. Papillary tumors 
are often associated with recurrence, but seldom invade muscularis propria or 
metastasize. Non-papillary tumors account for 20-30% of all bladder tumors, with muscle 
invasion present in 90% of these patients. In TCC, the recommended grading system is 
the WHO classification: 
 
Grade1 papillary TCC show an increased number of cell layers of superficial cells, there 
is reduced or absent cytoplasmic clearing, increased nuclear size, slight nuclear 
pleomorphism and slightly abnormal nuclear polarization, slight hyperchromatism, absent 
or rare mitoses and nuclear grooves are present. 
Grade 2 papillary TCC show a variable number of cell layers, absent superficial cells, 
often absent cytoplasmic clearing, increased nuclear size, moderate nuclear 
pleomorphism, abnormal nuclear polarization, moderate hyperchromatism, mitotic 
figures and nuclear grooves are present. 
Grade 3 papillary TCC show a variable number of cell layers, absent superficial cells, 
absent cytoplasmic clearing, greatly increased nuclear size, marked nuclear 
pleomorphism, absent nuclear polarization, marked hyperchromatism, prominent mitoses 
and absent nuclear grooves.    
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There are several staging systems that have been described for bladder cancer, one of the 
best known of which is AJCC/UICC (Table 1.1). Traditionally, Ta and T1 papillary 
urothelial carcinoma are called superficial cancer and T2 and above are termed as muscle 
invasive cancer. 
 
Table1.1: Pathological staging of bladder cancer (AJCC/UICC) (Syrigos et al., 1999) 
PATHOLOGICAL STAGING OF CARCINOMA OF THE URINARY BLADDER 



















Non-invasive papillary carcinoma 
Carcinoma in situ 
Tumor invades the lamina propria 
Tumor invades the muscularis propria (detrusor muscle) 
Superficial muscularis propria 
Deep muscularis propria 
Deep muscularis perivesical tissue 
Microscopically 
Macroscopically (extravesical mass) 
Invasion of adjacent structures 
Prostate, uterus, vagina 
Pelvic wall, abdominal wall 
Lymph node metastasis 
Regional node < 2 cm 
Regional node 2-5 cm 










1.2 THE TREATMENT OF BLADDER CANCER 
 
1.2.1 Surgical treatment and intravesical therapy of superficial TCC 
 
Seventy to 80% of the patients with TCC present with low-grade, noninvasive tumors or 
superficial papillary tumor confined to the mucosa. The standard primary treatment for 
superficial bladder cancer is endoscopic transurethral resection of the bladder tumor 
(TURBt). However after surgical treatment, 70% of TCC will recur and about 30% of the 
recurrent tumors present with higher grade and/or with muscle invasion. The high 
recurrence rate and the unpredictability of the progression patterns have led to the 
widespread use of intravesical chemotherapy or immunotherapy.  
 
The advantage of the intravesical route of administration are the high concentration of 
drug in contact with tumor-bearing mucosa or bladder epithelium at risk, and little or no 
systemic uptake of the drug. The commonly used intravesical agents in the treatment of 
bladder cancer include Bacillus Calmette-Guerin (BCG), thiotepa, mitomycin, 
doxorubicin, valrubicin, interferon, interleukin-2, keyhole limpet haemocyanin, 
bropirimine and levamisole. 
  
1.2.2 BCG therapy 
  
Among all these agents, BCG is favored as a first-line intravesical drug because of its 
well-documented effect on reducing tumor recurrences and tumor progression after 
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TURBt. A significant reduction in tumor recurrence is noted in most studies comparing 
BCG with TUR alone for superficial bladder cancer. Lamm reported that immunotherapy 
with BCG has resulted in complete tumor regression in one half of treated patients with 
papillary tumors and in more than 70% of those with carcinoma in situ (CIS) for 5 years 
or more (Lamm, 1992). In comparison, the existing studies of intravesical chemotherapy 
have failed to demonstrate significant reduction in long-term incidence of tumor 
recurrence. Moreover, intravesical BCG can also reduce the risk of tumor progression 
after transurethral resection to stage T2 disease or higher in patients with superficial 
bladder cancer. Sylvester et al followed up 4,863 patients for a median of 2.5 years and a 
maximum of 15 years. They found 260 of 2,658 patients on BCG (9.8%) had progression 
(T2 disease or higher) compared to 304 of 2,205 patients in the either resection alone or 
resection plus intravesical treatment other than BCG (13.8%), a reduction of 27% in the 
odds of progression on BCG (OR 0.73, p = 0.001) (Sylvester et al., 2002). However, 
compared with intravesical chemotherapy, intravesical BCG therapy appears to have 
more side-effects. Reported systemic side-effects include fever, flu-like symptoms, 
malaise, chills, pneumontitis, hepatitis, arthralgia, myalgia and rash. Local side-effects 
comprise BCG cystitis, dysuria, urinary frequency, hematuria, granulomatous prostatitis, 
epididyno-orchitis and urethral obstruction, etc. 
 
The anti-tumor mechanism of intravesical BCG therapy in superficial bladder cancer has 
not been elucidated. But two premises seem certain (Martinez-Pineiro et al., 1997). First, 
it is necessary to bring living bacteria in contact with tumor cells. Consequently 
attachment, retention and internalization of BCG would take place. Thereafter, the 
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induction of immunological events follows and this may lead ultimately to tumor 
destruction (Ratliff et al., 1987). Second, T lymphocytes are required for BCG-mediated 
anti-tumor activity, evidenced by the phenomenon that depletion of total T cell, Th or Tc 
subsets in mice eliminated BCG-mediated anti-tumor activity (Ratliff, 1992). The 
infiltration of a broad range of immunological cells, including macrophage, T 
lymphocytes and natural killer cells, is observed after intravesical BCG treatment.   
 
1.2.3 Treatment of invasive bladder cancer 
 
For invasive TCC, squamous cell carcinomas and adenocarcinoma, radical cystectomy 
plus urinary diversion is recommended to optimize the 5-year survival rate. Radical 
cystectomy refers to the removal of the anterior pelvic organs. In males it includes the 
resection of the prostate, seminal vesicles, bladder with its peritoneum, and perivesical 
fat. In females, it includes the urethra, bladder, cervix, vaginal cuff, uterus, ovaries, and 
anterior pelvic peritoneum. Partial cystectomy is also used to treat solitary, primary 
invasive TCC. But the biggest disadvantage of partial cystectomy is the high rate of 
tumor recurrence (Sweeney et al., 1992). Radiation and chemotherapy have been studied 
as bladder-sparing treatments for muscle-invasive TCC. Invasive TCC is sensitive to 
cytotoxic chemotherapy, but the majority of patients does not achieve a complete 
response and eventually succumb to progression of chemo-resistant disease (Shipley et 








Despite the efficacy of TURBt plus intravesical BCG immunotherapy, 30% of TCC 
patients will have tumor recurrence. As many as 30% of recurrent tumors will progress to 
higher grade or stage tumors, which can be potentially life-threatening (Soloway 1996; 
Nseyo et al., 1996; Saint et al., 2002). New treatment modalities must be developed to 
improve the overall treatment efficiency of TCC.  
 
The basic concept of human gene therapy was developed more than 20 years ago. Gene 
therapy for cancer has become a more realistic approach because rapid advances in 
molecular genetic techniques have revealed the alteration of cellular oncogenes and 
tumor suppressor genes in cancer cell. Gene therapy is defined as the treatment of an 
acquired or inherited disease by direct transfer of genetic material and genetic 
modification of genes expression in somatic cells. It is an attractive new approach for the 
treatment of bladder cancer for several reasons. Firstly, the unique isolated environment 
and the accessibility of the bladder make it an optimal candidate for gene therapy. 
Secondly, patients who have undergone TURBt have a low tumor burden and like 
patients with carcinoma in situ (CIS), their cancer cells are accessible to either viral or 
non-viral agents, so they provide the best chance for a gene-based immunotherapy to 
succeed. Thirdly, the response of the tumor to treatment can be easily determined with 
cystoscopy and urine cytology. 
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1.3.2 Gene delivery vectors 
 
 1.3.2.1 Viral vectors 
The therapeutic outcome for any form of gene therapy directly depends upon the 
availability of an efficient and safe delivery system. Currently, there are two major 
methods of delivering genetic material into target cells: non-viral and viral methods. 
Viral systems are the most commonly used gene transfer methods in gene therapy today. 
To construct a viral vector, a therapeutic gene is inserted into a modified viral genome, 
and a specific promoter such as the cytomegalovirus (CMV) promoter, is inserted into the 
viral genome to drive production of the therapeutic gene. Then the therapeutic gene is 
delivered into the target cells upon infection with the virus. Many kinds of viruses can be 
used to construct the viral vectors. The most widely used vector systems are adenovirus, 
retrovirus, herpes-simplex, vaccinia virus and adeno-associated virus. These viruses have 
different features in terms of the size of genes that can be carried, transfection efficiency, 
duration of expression and immunogenicity of the vector and transgene products (Table 
1.2). In general, viral vectors are more efficient than non-viral vectors in terms of 
transfection efficiency.  However, the risk of using live viruses in gene therapy protocols 
has always been of concern. Adenovirus, for example, was linked to the death of an18 
year-old patient at the University of Pennsylvania (Lehrman, 1999). Duplicate sequences 
not engineered in the original form were discovered from this patient’s organs after 

















Size 8 kb 7-8 kb 30 Kb 4.5 kb 30kb 
Integration Yes Occasional No Yes No 
Tissue 
specificity 
Yes Yes Yes No No 











Delivery Ex vivo or 
direct 
injection 
Ex vivo or 
direct injection, 
aerosolization 
Ex vivo or 
direct 
injection 
Probably ex vivo 
only 




106-10 9  108-1010  106-108 106-108 10 7 -10 9  
Duration of 
expression 




Moderate High Moderate Moderate High 















1.3.2.2 Non-viral vectors 
 
Non-viral vector systems are important because they do not carry most of the risks 
implicit in the use of viral vectors. Techniques for non-viral gene transfer include 
physical and chemical methods (Table 1.3). Liposomes and electroporation are the most 
widely used non-viral approaches and may be suitable for gene therapy in localized 





Table 1.3: Non-viral gene transfer methods (Peter et al., 2002) 
 
Method In vitro efficiency In vivo efficiency Stability 
Chemical  
    Liposomes 
    Calcium Phosphate co-precipitation 
Physical 
    Electroporation 
    Microinjection 
    Tissue-injection 
    Jet injection 
    Gene gun 
 
 
     Medium 
     Medium 
 
     Medium 
     High 
       - 
     High 
     High 
 
     Low 
     Impossible 
 
     Low-medium 
     Impossible 
     Low 
     Impossible 













1.3.2.3 Liposome system 
 
Liposome-based gene delivery is regarded as a promising gene transfer technique for 
gene therapy because of its safety, the lack of immnogenicity, unlimited size of DNA that 
can be delivered and relative ease in creating DNA-liposome complexes in large scale for 
use in the clinic. Generally, the liposomes can be grouped in two categories based on the 
mode of entrapment of DNA: positively charged or cationic liposome and negatively 
charged or anionic liposome or pH-sensitive Liposome (Table 1.4).  Cationic liposomes 
are more commonly used due to their relatively high transfection efficiency in various 
types of cell and tissue. Both cationic and anionic liposomes may share the same 
mechanism of liposome-cell interaction which can be divided in three steps: 
internalization of liposome-DNA complex, delivery of DNA into the cytosol and entry of 
DNA into the nucleus (Behr et al., 1989; Pinnaduwage et al., 1989; Gustafsson et al., 





Table 1.4: Two categories of liposome 
 
Categories Mode of Entrapment 
of DNA 
Gene Transfer Examples 
Cationic 
Liposome 
DNA remains outside 
to the positively 
charged liposomes 
due to the charge 
interactions. 
Efficient for gene transfer 
because of their stronger 
adherence to negatively 









DNA is entrapped in 
the negatively 
charged liposomes. 
Less efficient. Liposomes are 
destabilized in response to 
low pH in the endocytic 
vacuoles and release the 




Liposome-DNA complex can enter the cell by local destabilization of membrane, fusion 
or endocytosis. Endocytosis is the major mechanism for pH-sensitive liposome. Usually 
the non-specific cellular binding of pH-sensitive liposome is low. This binding ability can 
be significantly enhanced if an appropriate ligand, such as an antibody, is attached to the 
liposome surface. In contrast, cationic-DNA liposomes can binds cells more strongly due 
to favorable charge interactions. This may lead to the higher transfection efficiency of 
cationic liposomes compared to ligand-free, pH-sensitive liposomes.  
 
The second step is the delivery of DNA into the cytosol. For the liposome-DNA complex 
which enters the cell by local destabilization and fusion, DNA usually can be directly 
delivered to the cytosol. For those that enter by endocytosis, this leads to the formation of 
endosomes containing liposome-DNA complex. DNA can be released by the rupture of 
the endosome membrane. But unfortunately, many endosomes rapidly fuse with 
lysosomes and DNA is degraded subsequently.  
 
 12
The last step is the entry of DNA into the nucleus. Very little is known about how DNA 
moves from the cytosol into the nucleus. But Capecchi showed this process may be very 
inefficient, evidenced by the fact that the microinjection of DNA into cytosol induces 
much less gene expression than the injection of same amount of DNA into nucleus 
(Capecchi et al., 1980). 
  
1.3.3 Gene therapy strategies for bladder cancer 
 
The most common strategies in gene therapy of bladder cancer are immune inductive, 
corrective, cytotoxic gene therapy and anti-sense oncogene therapy. 
 
1.3.3.1 Immune inductive gene therapy 
 
Immune inductive strategies aim to enhance the host immune response by increasing the 
antigenicity of tumor cells or boosting host humoral and cellular immune response to any 
given tumor locally or systematically. There are mainly two treatment options designed 
to achieve the above aim: transferring co-stimulatory molecules for T-cell 
recognition/activation and transferring genes encoding for cytokines. B7, a co-stimulary 
molecule, has been tested in an attempt to enhance tumor antigenicity. B7 protein is 
usually expressed on macrophages and B cells and reacts with CD28 to activate T cells. 
Tumor cells typically do not express this molecule. Vaccination of B7-transfected tumor 
cells has been shown to generate an antitumor effect, eliminating established tumors 
(Fujii et al., 1996; Larchian et al., 2000). Gueguen et al obtained a panel of CTL clones 
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that can specifically lyse bladder tumor cells in a MHC class I-restricted fashion by 
stimulating blood lymphocytes with the B7-1 gene transfected bladder carcinoma cells. In 
bladder cancer, increased effort has been focused on modification of tumor and/or host 
immunogenicity by transferring cytokines genes, namely cytokine gene therapy. This will 
be discussed in detail in the section 4 of Introduction.  
 
1.3.3.2 Corrective gene therapy  
 
The goal of corrective gene therapy is to suppress the malignant phenotype of cancer 
cells or to restore the normal function of aberrant cells. The mutational loss of tumor 
suppressor genes and activation of oncogenes are important steps in malignant cell 
transformation. Under physiological conditions, both cell division enhancing oncogenes 
and cell division inhibiting tumor suppressor genes are in balance. Various mutations for 
both classes of genes have been reported for bladder cancer (Table 1.5). 
 
Mutations in tumor suppressor genes can shift the balance towards cell division. Transfer 
of the wild type genes into the cells may restore the cell cycle and apoptosis control. P53 
was selected as the first target for this therapeutic strategy to treat various malignancies 
because the expression of this gene is altered in more human cancers than any other 
known gene. Preclinical studies with adenovirus containing a wild-type p53 construct 
have shown that p53 transduction induces apoptosis and decreases cell proliferation in a 
number of cancer cell lines and in vivo as well (Nielsen et al., 1997; Spitz et al., 1996; 
Ohashi et al., 1999). In bladder cancer, the adenovirus-mediated transduction of wild-
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type p53 resulted in dose-dependent growth inhibition of bladder cancer cells in vitro 
(Irie et al., 2001). Shirakawa et al reported Ad-CMV-p53 induced higher levels of p53 
protein and mRNA in the drug-resistant bladder cancer cell lines than in the parental cell 
line and, consequently, higher levels of p21 and Bax mRNA, which resulted in higher 
percentages of G (1) cell-cycle arrest and apoptosis (Shirakawa et al., 2001). 
 
Table 1.5: Common oncogene and tumor suppressor gene mutation in bladder cancer 
(Peter et al., 2002) 
 









Tumor Suppressor gene 
Tumor Suppressor gene 
Tumor Suppressor gene 















The transfer of retinoblastoma (Rb) is also a common target for gene therapy. The Rb 
tumor suppressor gene is inactivated in at least 25%-50% of bladder cancers. Xu et al. 
used adenovirus to transfect Rb-defective human bladder cancer cell lines 5637 and HT 
1376 cells. The transfected cells demonstrated morphological changes as well as growth 
inhibition in a dose-and cell-type-dependent fashion (Xu et al., 1996). 
 
1.3.3.3 Cytotoxic gene therapy 
 
Cytotoxic gene therapy implies the selective destruction of cancer cell or cancer-bearing 
tissue. As the cells themselves generate the toxic product leading to their death, these 
 15
approaches are often called suicide gene therapy.  Several suicide systems are under 
investigation in an attempt to demonstrate a drug-induced killing of the cancer. Herpes 
simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) is one of the best established 
of these systems. Ganciclovir (GCV) is an acyclic nucleoside analogue that is not 
normally metabolized by mammalian cell thymidine kinase. However, HSV-tk is able to 
monophosphorylate the relatively non-toxic prodrug GCV. The product is subsequently 
metabolized by endogenous mammalian kinases into ganciclovir triphosphate, which is a 
purine analog that competes with normal nucleotides and can inhibit DNA polymerase 
and thus lead to cell death (Matthews et al., 1988; Moolten et al., 1986; Samejima et al., 
1995). In subcutaneous bladder cancer model, HSV-tk/GCV system has shown dramatic 
killing against cancer cell (Sutton et al., 1997; Freund et al., 2000). A potential problem 
for this system is the issue of tissue specificity. Ideally, the promoter used in HSV-
tk/GCV system should either be from a cancer-specific gene or from a tissue specific 
gene.  
 
Recently, attenuated, replication-competent herpes simplex virus (HSV) mutants such as 
G207 and NV1020 are attracting interest because of their ability to replicate within and 
kill tumor cells while remaining of low pathogenicity to normal tissue. G207 is 
genetically engineered oncolytic virus based on wild-type herpes simplex type-1. The key 
features of G207 include the deletion of both gamma (1) 34.5 genes and inactivation of 
ICP6 (ribonucleotide reductase) allows G207 to selectively replicate within tumor cells 
(Mineta et al., 1995; Yazaki et al., 1995). NV1020 is another attenuated recombinant 
herpes virus with deletions of the HSV joint region, with deletion of only one copy of the 
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gamma (1) 34.5 gene, and with the ICP6 gene intact (Delman et al., 2000; McAuliffe et 
al., 2000). Studies showed both these viruses were effective at infecting, replicating 
within, and achieving subsequent cell lysis for bladder cancer cells both in vitro and in 
vivo with a single intravesical instillation (Cozzi et al., 2001; Oyama et al., 2000). G207 
and NV1020 have potential for intravesical treatment of human bladder cancer.  
 
1.3.3.4 Anti-sense oncogene therapy 
 
As the activation of oncogenes and mutational loss of tumor suppressor genes are 
important steps in malignant cell transformation, anti-sense oncogene therapy has been 
designed to inactivate oncogenes, reverse the malignant phenotype, inhibit tumor and 
decrease tumorigenicity. Several strategies have been used: including anti-sense 
oligonucleotides and anti-oncogene ribozymes. Anti-sense oligonulceotides specifically 
inhibit the activities of various oncogenes and proto-oncogenes, presumably by binding 
to mRNA and inducing translation arrest (Mizutani et al., 1994; Li et al., 1996). Anti-
oncogene ribozymes are RNA molecules that exhibit specific catalytic activities. It can 
destroy RNA translation templates for “unwanted” gene products. Hammerhead 
ribozymes are one sub-group of ribozymes which can perform true enzymatic reactions 
and are named for their hammerhead-like structure (Sioud et al., 1999; Bi et al., 2001). 
Irie et al demonstrated intralesional injection of an adenovirus expressing an anti-H-ras 
hammerhead ribozyme resulted in significant antineoplastic effects in a dose-dependent 








Cytokines have been shown to play an important role in the regulation of the host 
antitumor immune response and the direction of the maturation, activation and migration 
of the inflammatory cells. But the clinical application of cytokines is hampered because 
of the severe side effects associated with the systemic administration of cytokine. For 
TNF-α, for example, the maximal tolerated dose in human being (10 µg/kg) is about 40-
fold less than the doses required to generate a significant anti-tumor response in mice 
(400µg/kg)(Asher et al., 1987). Additionally, their effectiveness is also decreased by the 
rapid elimination and short half-life when they are delivered systemically (Rosenberg et 
al., 1989; Lotze et al., 1985). Thus cytokine gene therapy is designed to circumvent these 
problems by transfecting the cytokine gene into tumor or carrier cells that will express the 
cytokine at the primary tumor site, mimicking paracrine cytokine release in vivo and 
enhancing the induction of tumor-specific immune response without many of the 
troublesome systemic side effects. 
 
1.4.2 Modality of gene transfer for cytokine gene therapy 
 
Depending on the approach of gene transfer, cytokine gene therapy can be divided into 
two general types: ex vivo transfection and in vivo tranfection (or in situ transfection). For 
ex vivo transfection, tumor cells are transfected with cytokine gene ex vivo, irradiated, 
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and injected to the host. The tumor cells transfected can be autologous or allogeneic. The 
use of autologous tumor cells requires that the patient’s tumor be surgically removed. 
This strategy has the advantage that the patient’s own tumor cells have the greatest 
chance to vaccinate against the spectrum of relevant tumor antigens both shared and 
unique to the individual. The strategy indeed has been shown to have the ability of 
inducing dramatic immune responses in experimental animals against parental 
unmodified tumor cells (Saito et al., 1994; Fearon et al., 1990). 
 
But the limitations in the ability to harvest, transfect gene ex vivo and re-inject the 
autologous tumors on a patient-by-patient basis raise questions about the feasibility of 
this strategy for clinical application. In contrast, the use of allogeneic tumor cells (a 
single standardized transduced cells line) is much less labor-intensive and time-
consuming. But its efficacy depends on whether the transduced cells share antigens with 
the patient’s tumor. For in vivo transfection, the cytokine gene is directly transferred to 
the tumor cells in vivo. No ex vivo tumor cell tranfection and re-injection are required. 
Many studies have been carried out to evaluate the efficacy of this strategy (Saffran et al., 
1998; Lee et al., 1994). 
 
1.4.3 Target cells of gene transfer in cytokine gene therapy 
 
Several types of cells have been used as targets for cytokine gene transfer of ex vivo gene 
transfection approach. For the most part, the cytokine gene therapy of cancer has 
involved the transfer of cytokine gene to tumor cells. Theoretically, this approach has 
advantages in that expression of the cytokine will be occurring in the same 
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microenvironment as expression of tumor antigens, which should facilitate a heightened 
immune response.  A number of studies have shown that the direct cytokine gene transfer 
to tumor cells renders them vulnerable to immune attack, enhancing the ability of the 
tumor to initiate a protective immune response. 
 
Recently, interest has also extended to transfection of other cell types, such as 
endothelium cells, dendritic cells, lymphocytes and fibroblast. Endothelial cells have 
been chosen as the targets for cytokine gene transfer because they function not only as a 
vascular framework for the intravascular delivery, but also as a source of cytokines that 
influence the growth and differentiation of neighboring vascular and parenchymal cells. 
The advantage of these cells is that they maintain their capacity to proliferate and offer a 
potential renewable and expandable source of therapeutic gene production at sites of 
tumor angiogenesis. Su et al injected highly metastatic human breast cancer cell line 
MDA-MB-435 with the genetically manipulated endothelial cells expressing IL-1α or IL-
2 into the mammary pad of nude mice (Su et al., 1994). The results showed that cytokine-
expressing endothelial cells not only inhibited the tumorigenesis of MDA-MB-435 cells, 
but also abrogated the formation of metastasis.   
 
Dendritic cells (DC) are the most effective antigen presenting cells and are critical for the 
induction of primary, cell-mediated immune responses due to their ability to acquire 
antigen in the peripheral tissue and process, transport, and present it to naïve or memory-
antigen-specific T cells in the secondary lymphoid organs (Steinman et al., 1991; Stingl 
et al., 1995). As the DC’s effectiveness in presenting tumor antigen is mainly modulated 
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by cytokines, cytokine gene transferred DC may be able to stimulate potent and Ag-
specific anti-tumor immune response. Nishioka et al showed intratumoral injection with 
IL-12 gene-modified bone marrow-DCs resulted in regression of day 7 established 
weakly immunogenic tumors (MCA205, B16, and D122) (Nishioka et al., 1999). Miller 
et al also found that intratumoral administration of adenoviral interleukin 7-transduced 
dendritic cells (DC-AdIL-7) resulted in complete tumor regression in two lung cancer 
models (Miller et al., 2000). Furthermore, all the DC-AdIL-7-treated mice completely 
rejected a secondary rechallenge, whereas the AdIL-7-treated mice had sustained 
antitumor effects in only 20-25% of the mice. 
 
1.4.4 Cytokines used in gene therapy of bladder cancer 
 
The direct modification of tumor cells using cytokine genes to increase host immunity 
has been studied intensively in experimental animals over the last decade. A number of 
cytokine genes have been demonstrated to have the ability of reducing tumorigenicity of 
cancer cells by stimulating localized inflammatory and/or immune response, including 
TNF-α, granulocyte-macrophage-colony stimulating factor (GM-CSF), granulocyte 
colony-stimulating factor (G-CSF), interleukin-1 (IL-1), IL-2, IL-4, IL-6, IL-7, IL-12, IL-
18, interferon gamma, etc. However, some cytokines also failed to show any properties in 
inducing immunity or deceasing tumorigenicity after they were transferred to tumor cells, 
such as IL-5 (Kruger-Krasagakes et al. 1993). Transforming growth factor-beta1 (TGF-
β1) modified Meth A sarcoma cells are even much more tumorigenic than parental cells 
(Chang et al., 1993; Torre-Amione et al., 1990). This strategy has been tested in many 
cancer models and the clinical trials are under going in various cancer patients such as 
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melanoma, renal cell carcinoma, colon cancer, lung cancer, brain tumor and lymphoma. 
In spite of the unique anatomy structure of bladder and the established role of intravesical 
immunotherapy with BCG for the treatment of bladder cancer, only a few cytokine gene 
therapy studies have been reported in bladder cancer, including ex vivo cytokine gene 
transfer strategy (vaccination) (Table 1.6) and in situ cytokine gene transfer strategy 
(Table 1.7).  
 
Table 1.6: Review of the studies on cytokine gene therapy of bladder cancer (ex vivo 
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1.5 CLINICAL TRIAL OF BLADDER CANCER GENE THERAPY IN THE 
NATIONAL INSTITUTE OF HEALTH 
 
To date, only a few clinical trials have been carried out or are on going in NIH (Table 
1.8). All of these trials use viral-vectors.  No cytokine gene therapy clinical trial has been 
done although this strategy has an apparent theoretical advantage in bladder cancer.   
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Table 1.7: Review of the studies on cytokine gene therapy of bladder cancer (in situ 
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group. 
 
Table 1.8: Clinical trial of bladder cancer gene therapy in NIH  
Trial title Institution Status Strategy Vector Reference
Phase I Study of 
Adenovirus p53 in 
Patients With Locally 
Advanced or Metastatic 
Bladder Cancer 
University 
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1.6 STUDY DESIGN 
 
The high tumor recurrence and progression rate after TURBt plus intravesical BCG 
therapy highlights the necessity of exploring other therapeutic approaches. Cytokine gene 
therapy is an attractive strategy for bladder cancer because: (a) The unique and isolated 
environment of the bladder makes it an optimal candidate for cancer gene therapy. (b) 
Superficial bladder cancer patients who have undergone TURBt have a low tumor burden 
and like patients with carcinoma in situ (CIS), their cancer cells are accessible to 
intravesical administration of viral or non-viral agents. Theoretically, these patients are 
expected to especially benefit from gene therapy. (c) The lack of response to BCG 
immunotherapy has been correlated with a reduction in cytokine production after BCG 
induction. This could reflect that in these patients the reduced cytokine levels may 
contribute to the poorer response to BCG therapy. Thus direct cytokine gene transfer 
could be an effective way to boost the immune system in these patients. (d) A number of 
studies have shown that introduction of cytokine genes into tumor cells can stimulate 
antitumor immune responses and lead to significant tumor suppression in various cancer 
models. Bladder cancer, which is known to well respond to immunotherapy with BCG, is 
a potential target for cytokine gene therapy.   
 
In recent years, several cytokine genes have been tested as candidates for cytokine gene 
therapy in bladder cancer such as interleukin-2, interferon-β and interleukin 12 with 
encouraging results. To date however, tumor necrosis factor-α (TNF-α) has not been 
evaluated by direct gene transfer in bladder cancer although TNF-α protein possess 
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potent multiple anti-tumor effects and the data in laboratory and clinical studies 
demonstrated its effectiveness in inhibiting bladder cancer.  
 
The recent report of the induction of leukemia-like symptoms in children treated with 
retroviruses and the limited transfection of urothelial cells in the bladder by adenoviruses 
in spite of the presence of human coxsackie-adenovirus receptor (hCAR) highlight some 
of the problems associated with viral gene therapy.  We therefore explored a novel non-
viral transfection system comprising DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium methyl-sulfate) plus methyl-beta-cyclodextrin solubilized 
cholesterol (MBC) which we have previously demonstrated to efficiently transfect 
urothelial cells both in vitro and in vivo using the β-galactosidase reporter gene 
(Lawrencia et al., 2001). The addition of MBC, a complex which may be capable of 
donating cholesterol to the cell membranes and affect the fluidity/ permeability of the cell 
membrane, to DOTAP can improve the transfection efficiency by 3.8 fold (Lawrencia et 
al., 2001). 
 
The aim of this study is to evaluate the feasibility and efficacy of cytokine gene therapy 
using DOTAP plus MBC as gene deliver system and mouse TNF-α gene as therapeutic 
gene. To mimic clinical condition, an orthotopic murine model of bladder cancer was 









2.1.1 Chemicals and biological reagents 
 
Absolute Alcohol                                                         (Merck Darmstadt, Germany)  
Acetone                                                                        (BDH Lab Supplies, England) 
Agarose                                                                        (Promega, Madison, WI) 
Annexin-V-FLUOS                                                      (Roche Diagnostics,  
                                                                                      Mannheim, Germany)  
Aprotinin                                                                      (Sigma, St. Louis, MO) 
ß-mercaptoetharol                                                         (Sigma, St. Louis, MO) 
BSA (100×)                                                                   (Promega, Madison, WI) 
Buffer J (10×)                                                               (Promega, Madison, WI) 
Buffer K (10×)                                                              (Promega, Madison, WI) 
Calf Intestinal Alkaline Phosphatase  
(CIAP) (1 uint/µl)                                                          (Promega, Madison, WI) 
Cholesterol-Water Soluble                                            (Sigma, St. Louis, MO) 
DNA Ladder (1 Kb)                                                       (Promega, Madison, WI) 
Deoxyribonucease I                                                       (Invitrogen, Carlsbad, CA) 
Diethyl Pyrocorbonate (DEPC)                                     (Sigma, St. Louis, MO) 
DNA Polymerase Ι Large (Klenow) Fragment              (Promega, Madison, WI) 
DNA Ligase                                                                   (Promega, Madison, WI) 
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Dnase Buffer                                                                   (Gibco BRL, Rockville, MD) 
dNTP (100 mM)                                                             (Promega, Madison, WI) 
EcoR I (10 units/ul)                                                        (Promega, Madison, WI) 
Ethidium Bromide                                                          (Sigma, St. Louis, MO) 
Eosin                                                                               (Sigma, St. Louis, MO) 
Ethylene Diamine-Tetra-acetic Acid (25 mM)               (Gibco BRL, Rockville, MD) 
 
Fetal Bovine Serum (FBS)                                             (HyClone, Logan, UT) 
Formaldehyde                                                                 (Sigma, St. Louis, MO) 
Glutaraldehyde (25%)                                                     (Sigma, St. Louis, MO) 
Glycerol                                                                          (Merck Darmstadt, Germany) 
Hepes Buffer Solution (1M)                                            (Gibco BRL, Grand  
                                                                                     Island, NY, USA) 
Hematoxylin                                                                    (Sigma, St. Louis, MO) 
Igepal CA 630                                                                 (Sigma, St. Louis, MO) 
Ligase Buffer (10×)                                                         (Promega, Madison, WI) 
Isopropanol                                                                      (Sigma, St. Louis, MO) 
LB Medium (Low Salt)                                                    (NUMI, Sinagpore) 
LB Medium (Normal Salt)                                               (NUMI, Sinagpore) 
Load Dye (6×)                                                                  (Promega, Madison, WI) 
L-glutamine (200mM)                                                     (Sigma, St. Louis, MO) 
Magnesium Chloride (25mM)                                          (Promega, Madison, WI) 
Magnesium Chloride                                                         (Merck Darmstadt, Germany) 
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Magnesium sulfate                                                            (Merck Darmstadt, Germany) 
Mineral Oil                                                                        (Sigma, St. Louis, MO) 
Mounting Medium                                                            (Surgipath, Canada) 
N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N- 
trimethylammonium methylsulfate (DOTAP)                   (Roche Diagnostics,    
Mannheim, Germany) 
O-Nitropnenyl-ß-Galactopyranoside (ONPG)                  (Sigma, St. Louis, MO) 
pBud.CE4.1                                                                       (Invitrogen, Carlsbad, CA) 
pCMVlacZ                                                                         (Clontech, Pala Altho, LA) 
Penicillin-Streptomycin Solution                                      (Sigma, St. Louis, MO) 
Penicillin                                                                            (Sigma, St. Louis, MO) 
Pepstatin                                                                             (Sigma, St. Louis, MO) 
Phenyl Methyl Sulforyl Fluoride                                       (Sigma, St. Louis, MO) 
Phosphate Buffered Saline (×10)                                       (NUMI, Singapore) 
Potassium Ferricynaide                                                      (Sigma, St. Louis, MO) 
Potassium Ferrocynaide                                                     (Sigma, St. Louis, MO) 
Potassium Chloride                                                             (Merck Darmstadt, Germany)  
Propidium Iodide (PI)                                                         (Sigma, St. Louis, MO) 
Taq DNA Polymerase (5U/ul)                                            (Promega, Madison, WI) 
Thermophilic DNA Poly 10×Buffer                                   (Promega, Madison, WI) 
Reverse Transcriptase                                                         (New England Biolab, Beverly,   
MA) 
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Reverse Transcriptase Buffer                                           (New England Biolab, Beverly, 
MA) 
Rnase A                                                                            (Sigma, St. Louis, MO) 
RNAsin                                                                             (Promega, Madison, WI) 
RPMI 1640                                                                       (NUMI, Sinagpore) 
Sac I (10 units/ul)                                                             (Promega, Madison, WI) 
Sca I(10 units/ul)                                                              (Promega, Madison, WI) 
Sodium Acetate Buffer Solution (3M)                             (Sigma, St. Louis, MO) 
Sodium Azide                                                                   (Sigma, St. Louis, MO) 
Sodium Carbonate                                                            (Merck Darmstadt, Germany) 
Sodium Chloride                                                               (Merck Darmstadt, Germany) 
Sodium Dihydrogen Phosphate Dihydrate                       (Merck Darmstadt, Germany)  
Sodium Fluoride                                                               (Merck Darmstadt, Germany) 
Sodium Hydrogen Phosphate Anhydrous GR                  (Merck Darmstadt, Germany) 
Sodium Hydroxide                                                            (Merck Darmstadt, Germany) 
Trypan Blue                                                                       (Sigma, St. Louis, MO) 
TRIzol TM                                                                            (Life Technologies, Inc.        
Gaithersburg, MD) 
X-gal                                                                                  (Bio-Rad, Herclues, CA)  
Xylene                                                                               (Merck Darmstadt, Germany) 




2.1.2 Commercial kits 
 
ABI Prism BigDye Terminator v3.0 Ready Reaction 
Cycle Sequencing Kit                                                                 (Applied Biosystems) 
Endofree QIAGEN Plasmid Purification Kit                             (QIAGEN) 
Mouse TNF-α ELISA Kit                                                          (Endogen, Pierce 
Biotechnology, Inc.Rockford, IL) 
Micro BCA Protein Assay System                                             (PIERCE, Rockford, IL) 
QIAquick Gel Extraction Kit                                                      (QIAGEN) 




FITC anti-mouse CD3                                                                 (BD PharMingen,USA) 
Hamster anti-mouse B7-1 mAb                                                   (BD Pharmingen,USA) 
Hamster anti-mouse ICAM I mAb                                              (BD Pharmingen,USA) 
Hamster anti-mouse Fas mAb                                                     (BD Pharmingen,USA) 
Mouse anti-mouse H-2K b /H-2D b MHC I mAb                          (BD PharMingen,USA) 
Mouse anti-mouse I-A b  MHC II mAb                                        (BD Pharmingen,USA) 
PE anti-mouse CD8a                                                                    (BD PharMingen,USA) 
PE anti-mouse NK cells/2B4                                                        (BD PharMingen,USA) 
PE anti-mouse CD4                                                                      (BD PharMingen,USA) 
Purified mouse IgG2a, κ isotype standard                                    (BD Pharmingen,USA) 
 30
Purified biotin polyclonal hamster IgG                                      (BD Pharmingen,USA) 
Purified rat IgG2a, κ isotype standard                                        (BD Pharmingen,USA) 
Rabbit anti-mouse Ig-FITC                                                        (Dako, Danmark)  
Rabbit anti-hamster IgG-FITC                                                   (BD Pharmingen,USA) 
 
2.1.4 Oligonucleotide primers 
 
Mouse TNF-alpha Primer                                                          (Research Biolabs,  
                                                                                                    Singapore) 
Mouse GAPDH primer                                                               (NUMI, Singapore) 
Mouse Fas Primer                                                                       (NUMI, Singapore) 
Oligo dT                                                                                      (NUMI, Sinagpore)   
pBud CMV Forward Primer                                                       (Invitrogen, Carlsbad, CA) 
pBud CMV Reverse Primer                                                        (Invitrogen, Carlsbad, CA) 
 
2.1.5 Cell line and mouse strain  
 
The murine transitional cell carcinoma cell line MB49 was obtained from Dr. Timothy 
Ratliff (University of Iowa, USA).  
 
Female C57BL/6 mice (4-6 weeks) were purchased from the Laboratory Animal Center 
(LAC, Sembawang, Singapore). All animals were kept at the Animal holding Unit 
(National University of Singapore) and allowed to acclimatize for 1 week prior to the 
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study. All animals were kept in a photo-periodic room with artificial light.  Animals were 
fed on standard laboratory chow and water was given ad libitum. The room temperature 





2.2.1 Cell culture 
 
MB49 cells were maintained in RPMI 1640 containing 10% fetal bovine serum (FBS), 
2mM L-glutamine, 50 U/ml penicillin and 0.05 mg/ml streptomycin at 37°C in a 
humidified chamber with 5% CO2. The prepared medium was stored at 4°C. All the cell 
lines were grown in plastic culture flasks (Zellkultur-Produkte, Switezerland).  For 
maintenance, cells were passaged every 4-6 days by diluting 1 ml cell suspension in 11 
ml fresh medium. The cells were dislodged by scraping with a cell scraper (Nunc, 
Denmark). 
 
2.2.2 In vitro transfection optimization using reporter gene pCMVlacZ 
 
Briefly, 2x10 5 MB49 cells were plated per well in 6-well tissue culture plates 24 hours 
before transfection. After three washings with blank RPMI 1640, 1 ml of blank RPMI 
1640 medium was added to the cells. To prepare the transfection reagent, 20 µg of 
DOTAP and 40µg of methyl-β-cyclodextrin solubilized cholesterol(MBC) was diluted to 
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a final volume of 87 µl with 20mM Hepes buffer and different amounts (1µg, 2.5µg, 5µg, 
7.5µg, 10µg) of pCMVLacZ were diluted to a final volume of 75 µl in 20mM Hepes 
buffer. The plasmid solution was added to the DOTAP/MBC mixture and incubated at 
room temperature for 15 minutes. Thereafter, this transfection reagent was added into the 
medium and incubated with MB49 cells for 2 hours at 37 °C. Then the medium was 
removed and the cells were washed, cultured for 48 hours in 3 ml of completed RPMI 
1640. X-gal staining and ONPG assay was performed to access the transfection 
efficiency and galactosidase activity 48 hours after transfection. 
 
X-gal staining 
In brief, cells were washed 3 times with 1×PBS and fixed in 0.05% glutaraldehyde 
(GTA). The cells were then stained with X-gal solution (1mg/ml in 5mM potassium 
ferricynaide and 5mM potassium ferrocynaide, 2mM magnesium chloride, in Tris buffer 
(pH 8.5) for 4 hours. Transfection efficiency was determined by counting the number of 
blue colonies relative to the total number of cells in five quadrants at ×100 magnification. 
Transfections were performed in duplicates and repeated three times.  
 
O-Nitropnenyl-ß-Galactopyranoside (ONPG) assay for transfection 
After 48 hrs the cells were washed three times with 1×PBS, scraped and transferred to 
Eppendoff tubes. The cells were lysed with 150µl of lysis working solution. One ml lysis 
working solution consists of 1 ml lysis buffer, 10 µl Igepal CA 630, 0.2 µl Aprotinin(10 
mg/µl), 10  µl PMSF(100mM) and 1 µl Pepstatin (1 mg/ml). Lysis buffer consists of 10 
mM Tris-Hcl, 5mM EDTA, 150 mM Nacl and 50 mM NaF. 
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The protein content of the lysates was measured by the Micro BCA Protein assay system 
with bovine serum albumin as a standard. Fifty µg of cell protein lysates were assayed in 
a reaction mixture containing 4mg/ml of ONPG (dissolved in Z buffer) and incubated at 
37°C for 1 hour. Z buffer consist of 60mM Na2HPO4, 40mMNaH2PO4, 10mM KCl, 1 
mM MgSO4.7H2O, 50mM ß-mercaptoetharol and was adjusted to PH=7.0.  Reactions 
were stopped by the addition of 500ul 1M Na2CO3 and the optical densities (OD) λ=420 
were measured. 
 
2.2.3 Construction and cloning of mouse TNF-α encoding plasmid 
 
2.2.3.1 Preparation of insert fragment for cloning 
The mouse TNF-alpha cDNA was digested from pCIneo-mTNF-α using EcoRI. Two µg 
of pCIneo-mTNF-α, 5 µl of universal buffer, 5 µl of BSA (10 x), 2 µl of EcoR I (24 
units/ul) in a total volume of 50 µl was incubated at 37 °C for 1 hour.  
 
2.2.3.2 Preparation of vector for cloning 
This vector was chosen because it has two multiple cloning cites. Two µg of pBud.CE4.1 
was incubated with 2 µl of Sca I(10 units/ul), 5 µl of buffer K, 5 µl of BSA (10 ×) in a 
total volume of 50 µl was incubated at 37 °C for 1 hour. 
 
Thereafter 2 µl of Calf Intestinal Alkaline Phosphatase (CIAP) (1 uint/µl), 10 µl of 10x 
CIAP buffer and 38 µl water were added to the above digested DNA to make up a total 
volume of 100 µl and incubated at 37 °C for 1 hour. 
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2.2.3.3 Gel electrophoresis for insert DNA and vector and gel extraction 
Insert DNA fragment and vector were separated by electrophoresis through 0.7% of 
agarose gels that contained 0.5 µg/ml ethidium bromide. To extract and purify the insert 
DNA and vector, the DNA was excised from the agarose gel with a clean, sharp scalpel 
and weighed, then purified with QIAquick gel extraction kit. Briefly, 3 volumes of buffer 
QG were added to the 1 volume of gel slices and incubated at 50°C for 10 minutes. After 
checking the color of the mixture was yellow, 1 gel volume of isopropanol was added to 
the samples. To bind DNA, the samples were applied to the QIAquick column and 
centrifuged for 1minute. The columns were washed with 0.75 ml of buffer PE and 
centrifuged for 1 min. The flow-through was discarded and the columns were centrifuged 
for an additional 1minute at 13,000 rpm.  Thereafter, 30 µl of buffer EB was added to the 
center of QIAquick columns and centrifuged for 1 minute at 13,000 rpm. 
 
2.2.3.4 Filling in reaction, gel electrophoresis and gel extraction for insert DNA  
To convert TNF-α from 3’ overhang obtained from EcoR I digestion to blunt end, 5 µl of 
Klenow buffer (10×), 5 µl of BSA (10 ×), 1 µl of dNTP (2mM), 1 µl Klenow DNA 
polymerase and 8 µl sterile water were added to the above 30 µl purified insert DNA and 
incubated at room temperature for 20 minutes. The product was separated by 
electrophoresis through 0.7% of agarose gels that contained 0.5 µg/ml ethidium bromide 
and extracted using QIAquick gel extraction kit.  
 




2.2.3.5 Ligation of vector and insert DNA 
To obtain the optimal ratio of vector to insert DNA, a 1:3 molar ratio of pBud.CE4.1: 
TNF-α were incubated with 2 µl of T4 DNA ligase and 2 µl of 10 x ligase buffer at 4 °C 
overnight.  
 
2.2.3.6 Preparation of competent cells 
A single colony of E.coli (DH5α strain) was used to inoculate a starter culture consisting 
of 10ml LB medium. The culture was grown for 8 hours at 37°C with vigorous shaking at 
200rpm. To set up the large culture, 2ml of the starter culture was used to inoculate 
200ml of LB medium in a sterile 1litre flask. The culture was grown at 37°C with 
vigorous shaking to an OD600 around 0.45. The culture was then aliquoted into four 50ml 
centrifuge tubes and centrifuged at 3000x g (Beckman JA-14 rotor), 4°C for 10 minutes. 
The supernatant was poured off and each pellet was resuspended in 2ml of ice-cold 0.1M 
CaCl2 solution and left overnight at 4°C. Cells were then mixed with 15% glycerol and 
aliquoted into 1m cryo tubes and stored at -70°C. 
2.2.3.7 Transformation  
After ligation, 100 µl aliquot of rapidly thawed competent cells was dispensed into each 
Eppendoff tube. Tubes were gently swirled to mix contents and stored on ice for 30 
minutes. Tubes were then transferred to a 42 °C waterbath and shocked for 2 minutes. 
Thereafter 0.5 ml of LB medium (low salt) was added and the cells were placed in a 37°C 
waterbath for 30 minutes. Then the cells were pelleted at 14,000 for 2 minutes and the 
supernatant was removed. The transformed cells were resuspended in 30 µl LB medium 
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(low salt), then transferred to LB (low salt)/Zeomycin (25 µg/ml) containing agar plates 
and gently spread using a sterile bent glass rod.  The plates were inverted and incubated 
at 37°C overnight. 
 
2.2.3.8 Culture of colony and miniprep of plasmid 
The colonies were randomly picked up and each of them was inoculated into 3 ml of LB 
medium (low salt) /Zeomycin (25 µg/ml) by a sterile yellow tip. The cultures were 
allowed to grow overnight at 37°C before they were pelleted (1.5 ml culture from each 
tube) for Minipreps using Wizard Plus SV Minipreps DNA Purification system. 
 
Briefly, the pellets were resupended with 250 µl cell resuspension solution. Then 250 µl 
cell lysis solution was added to each sample and the samples then were inverted for 4 
times to mix. After adding 10 µl alkaline protease solution, the samples were inversed for 
4 times and incubated at room temperature for 5 minutes. Thereafter 350 µl neutralization 
solution was added into each the samples. The samples were centrifuged at top speed for 
10 minutes at room temperature. The cleared lysates were then decanted into spin 
columns. After centrifugation of spin column, 750 µl of washing solution (ethanol added) 
were added to each column and then centrifuged. At last, 100 µl of nuclease-free water 
was added to the spin columns and the columns were transferred to sterile 1.5 
microcentrifuge tubes for centrifugation to elute the plasmid DNA.  The DNA was stored 




2.2.3.9 Positive colony screening and streaking 
To confirm the presence of insert fragment mTNF-α cDNA and its orientation, 5 µl 
plasmid DNA obtained from Minipreps was digested by 0.5µl Sac I with 1 µl 10x buffer 
J, 1 µl BSA (10x) in a total volume of 10 µl at 37°C for 1 hour. Then the digested 
plasmid was separated by electrophoresis through 0.7% of agarose gels that contained 0.5 
µg/ml ethidium bromide. 
 
The cultures from positive colonies were streaked on LB (low salt)/Zeomycin (25 µg/ml) 
containing agar plates again. A single colony was picked up from each plate and cultured 
as described above.  The miniprep was carried out, followed by Sac I screening again.  
The confirmed positive cultures were stocked at -80 °C in 15% of Glycerol. 
 
2.2.3.10 Sequencing of insert fragment mTNF-α 
The mTNF-α cDNA was confirmed by sequencing. 
 
Quantitation of plasmid concentration: The concentration of pBud-TNF-α obtained for 
minipreps was determined by measuring the absorbance (260nm and 280nm) using 
spectrophotometer (Shimadzu, UV-1201, Japan). One OD at 260 nm equals to 50 µg/ml 
DNA. 
 
Performing cycle seqencing: ABI Prism BigDye Terminator v3.0 Ready Reaction Cycle 
Sequencing kit was used to perform cycle sequencing. Five hundred ng pBud-TNF-α was 
mixed with 8 µl of terminator ready reaction mix, 3.2 pmol CMV Forward primer in a 
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total volume of 20 µl. The PCR reaction was consisted of 30 cycles of denaturation at 
96°C for 30 seconds, primer annealing at 50°C for 30 seconds and DNA synthesis at 
60°C for 30 seconds. Another reaction using CMV Reverse primer was run concurrently. 
 
Purification of extension product: Eighty µl of ethanol/sodium acetate solution consisting 
of 3 µl of 3 M sodium acetate, PH 4.6, 62.5 µl of non-denatured 95% ethanol and 14.5 µl 
of deionized water was added to each PCR product and vortexed. The tubes were left at 
room temperature for 15 minutes to precipitate the extension products. The tubes were 
then centrifuged for 20 minutes at the maximum speed. The supernatant of each sample 
was carefully aspirated and discarded. Thereafter, 250 µl of 70% ethanol was added to 
each tube and mixed. The tubes were centrifuged for 5 minutes at the maximum speed. 
The supernatant was aspirated and the samples were put in a heat block at 75°C until they 
were dry.  
 
Automated sequencing:  The dry tubes containing samples were then sent to the 
sequencing facility at NUMI for automated sequencing.  
 
2.2.3.11 Maxiprep of pBud-TNF-α for transfection 
The Endofree QIAGEN plasmid purification kit was used for the isolation of pBud-TNF-
α. A single colony was used to inoculate a starter culture consisting of 2-5ml LB medium 
containing 50µg/ml of ampicillin. The culture was grown for 8 hours at 37°C with 
vigorous shaking at 200rpm.  To set up the large culture, the starter culture was diluted 
1/500 to 1/1000 into 200ml of LB medium containing 25µg/ml of zeomycin and the 
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culture was grown overnight at 37°C with vigorous shaking at 200rpm. The cells were 
harvested by centrifugation (6000 x g, Beckman JA-14 rotor, 4°C, 10 minutes) and the 
bacterial pellet was resuspended in 10ml of Buffer 1 (50mM Tris-HCL (pH 8), 10mM 
EDTA and 100µg/ml Rnase A). Bacterial cells were lysed with 10 ml of Buffer 2 
(200mM of NaOH and 1% (w/v) SDS). After gentle mixing, 10 ml of Buffer 3 (3M 
potassium acetate pH 5.5) was added and the contents were thoroughly mixed by 
inversion. The cell debris and chromosomal DNA were removed by filtering through a 
QIAfilter cartridge. To remove endotoxins 2.5ml of ER buffer was added to the filtered 
lysated and incubated on ice for 30 minutes. The lysate was then loaded onto a pre-
equilibrated QIAGEN column by gravity flow. The salt and pH conditions of the lysate 
and the selectivity of the QIAGEN resin ensure that only plasmid DNA binds. The 
QIAGEN-tip is then washed with Buffer QC (1M NaCl, 50mM MOPS, pH 7 and 15% 
isopropanol) to remove any nucleic acid binding proteins. The plasmid DNA was eluted 
with a high salt buffer QN (1.6M NaCl, 50mM MOPS, pH 7 and 15% isopropanol).  The 
eluted DNA was percipitated with 10.5ml of isopropanol and the nucleic acids was 
pelleted by centrifugation (14000 x g, Beckman JA-20 rotor, 4°C, 30 minutes). The pellet 
was washed with 70% endotoxin free ethanol to remove residual salt and isopropanol the 
nucleic acids were pelleted by centrifugation (14000 x g, Beckman JA-20 rotor, 4°C, 10 
minutes). The purified DNA was briefly air-dried and redissolved in 200ul of endotoxin 





2.2.4 In vitro TNF-α transfection  
 
Briefly, 2x10 5  MB49 cells were plated /well on 6-well tissue culture plates 24 hours 
before transfection. Transfection was carried out as described before except that 2.5µg 
pBud-TNF-α was used. 
  
2.2.5 In vitro TNF-α expression 
 
The culture medium was collected 48 hours after transfection from MB49 cells 
transfected with pBud-TNF-α and centrifuged at 4000 rpm for 10 min at 4°C and kept at 
-80°C for later bioassay. The TNF-α expression level was measured using the mouse 
TNF-α ELISA kit according to the manufacturer’s direction.  
 
Briefly, the supernatants were thawed to room temperature before performing the ELISA. 
The provided TNF-α protein standard was reconstituted in blank RPMI 1640. Fifty µl of 
standards and samples were added in the 96-microtiter plate in duplicate. After 2 hours of 
incubation at room temperature, the unbound substances were washed away with wash 
buffer. Then 100 µl of prepared Streptavidin-HRP solution was added to the plate and 
incubated for 30 minutes at room temperature. Following five washings, 100 µl of TMB 
substrate solution was added to the wells to incubate for 30 minutes. The enzyme reaction 
was stopped and colorimetric results were read at 450 nm using a microplate reader with 
a reference wavelength of 550 nm for the correction of optical imperfections in the 
microtiter plate. The sample values were calculated from the standard curve using curve-
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fitting software GraphPad Prism 3.0. The supernatant collected from untransfected cells 
and pBud transfected cells served as controls. 
 
2.2.6 Cell counting after transfection 
 
To test whether pBud-TNF-α has an anti-proliferative effect against bladder cancer cells, 
the cell number of pBud-TNF-α transfected cells were counted and compared with that of 
parent cells and pBud transfected cells 48 hours after transfection. Aliquots of cell 
suspension were diluted with equal volumes of 0.1% trypan blue in the saline.  The cells 
were harvested and counted. The experiment was carried out in duplicate for three times. 
 
2.2.7 In vitro killing of bladder cancer cell line with pBud-TNF-α 
 
2.2.7.1 Cell cycle analysis 
Propidium iodide (PI) staining was performed to detect late apoptotic and dead cells with 
disrupted plasma and nuclear membrane. Ten thousand events were acquired in each 
sample. Pre-G1 cells were regarded as apoptotic cells. 
 
Two days after transfection, the cells were washed twice with PBS-glucose filtered 
sample buffer. The cells were removed by cell scraper. The cells were then resuspended 
in 1 ml of sample buffer for cell counting. 1x10 6  cells were taken from each sample for 
further fixing. The cells were centrifuged, and the supernatant was removed. For fixing, 1 
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ml ice-cold ethanol was added to the cell pellet drop by drop while vortexing the cells. 
The cells were fixed in the ethanol overnight at 4°C. 
 
The fixed cell sample was vortexed and centrifuged at 12,000 rpm for 2 min before the 
70% ethanol was poured off. Cells were gently resuspended in residual ethanol. 0.5 ml PI 
staining solution composed of 25 µl PI stock (1mg/ml), 57 Kunitz units Rnase A and 0.5 
ml sample buffer was added to each sample. Samples were incubated in the dark at room 
temperature for at least 30 minutes.  Analysis was carried out within 24 hour on a flow 
cytometry (Beckman Coulter Epics Elite ESP, USA). 
 
2.2.7.2 Annexin V staining  
To detect early apoptotic cells that expressed extracellular phosphatidylserine after pBud-
TNF-α transfection, Annexin-V-FLUOS staining was carried out. Briefly, the cell was 
washed with 1×PBS for three times and flushed with 1ml of 1×PBS. After centrifugation 
at 7000 rpm for 3 minutes at 4 °C, the cell pellet was resupended in 100 µl incubation 
buffer containing 10 mM Hepes/NaOH (PH4), 140 mM NaCl and 5 mM CaCl2. Then 2µl 
Annexin-V-FLUOS was added into the cells and incubated at room temperature for 10-15 
minutes. Thereafter, 0.3 ml incubation buffer was added to each tube. The cells were 






2.2.8 Flow cytometric analysis for surface immuno-related molecules 
 
The effect on up-regulating immuno-related molecule was examined by flow cytometry 
48 hours after pBud-TNF-α transfection, the cells were washed, scraped and then 
transfered to tubes. After centrifugation, the cells were divided into desired tubes and 
resuspended in 100 µl 1% BSA in PBS. The cells were stained by 2 µl of purified mouse 
anti-mouse H-2K b /H-2D b MHC I monoclonal antibody (mAb), mouse anti-mouse I-A b  
MHC II mAb, hamster anti-mouse B7-1 mAb, hamster anti-mouse ICAM I mAb and 
hamster anti-mouse Fas mAb and corresponding isotype-matched nonspecific control 
antibodies (purified mouse IgG2a, κ isotype standard, purified biotin polyclonal hamster 
IgG, purified rat IgG2a, κ isotype standard) for 20 minutes at 4°C . After washing, the 
cells were then stained by 2 µl of Rabbit anti-mouse Ig-FITC or anti-hamster IgG-FITC 
for 20 minutes at 4°C. The cells were washed again and fixed in 0.1% formaldehyde 
overnight at 4°C and analyzed by flow cytometry. The untransfected and pBud 
transfected cells are stained in the same way as controls. 
 
2.2.9 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis of TNF-
α expression in vivo 
 
TNF-α mRNA expression level was determined by RT-PCR. Total RNA was isolated 
from mouse bladders (with no tumor orthotopically implanted) 2 days after one 
intravesical instillation of pBud-TNF-α using TRIzol TM according to the manufacturer’s 
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instruction. Total RNA extracted from mouse bladder which was transfected with pBud 
was served as control.  
 
RNA extraction: A mouse bladder was homogenized with 1 ml of TRIzol TM using a 
homogenizer (Heidolph DIAX900, Germany). The homogenized samples were incubated 
for 5 minutes at room temperature.  Then 0.2 ml of chloroform was added into the 1 ml of 
TRIzol and mixed for 15 seconds, incubated at room temperature for 3 minutes followed 
by centrifugation at 12,000 rpm for 14 minutes at 4°C. Following centrifugation RNA 
remained at the colorless upper aqueous phrase. RNA was removed and precipitated by 
mixing with 0.5 ml of isopropanol and centrifugation at 12,000 rpm for 10 minutes at 4 
°C. RNA pellet was washed in 75% ethanol and centrifuged at 7,500 rpm for 5 minutes at 
4°C. Thereafter RNA was resuspended in 25 µl of RNase-free DEPC (0.1%v/v) water. 
 
RNA yield: RNA yield was estimated by measuring the absorbance (260nm and 280nm) 
using spectrophotometer (Shimadzu, UV-1201, Japan). One OD at 260 nm equals to 40 
µg/ml RNA.  
 
Dnase treatment: One µg total RNA from each sample was treated by incubating with 1 
µl of Dnase, 1 µl of 10× Dnase buffer, 0.5 µl of RNAsin and DEPC water in a total 
volume of 10 ul for 15 min at room temperature. The reaction was stopped by adding 1 µl 
of 25 mM EDTA to the above solution and incubating at 65°C for 10 minutes.  
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Complementary DNA synthesis: One µl of Oligo dT (3 pmol/µl), 0.4 µl of reverse 
transcriptase, 2.5 µl of 10× reverse transcriptase buffer, 0.25 µl of RNAsin, 1 µl of 25 
mM nucleotide were added to the above reaction solution. The volume was increased to 
25 µl with DEPC water and tubes incubate for 1 hour at 37°C. After adding 225 µl of TE 
buffer to the above mixture, the cDNA was stored at -20°C until further use. 
 
Polymerase chain reaction (PCR):  The Full-length of TNF-α coding sequence was 
amplified from cDNA by using primer 5′ -ATGAGCACAGAAAGCATGATC-3′(sense) 
and 5′-TCACAGAGCAATGACTCCAAA-3′(antisense). As a control, a 237-bp fragment 
of murine GAPDH was amplified from the same RNA preparation by using primer 5′-
TTCACCACCATGGAGAAGGC-3′ (sense) and 5′-GGAATGGACTGTGGTCATGA-3′ 
(antisense). PCR was performed by incubating 2.5-5 µl of RT-mixture with 0.5µM of 3′ 
and 5′ gene specific primer, 0.2 mM of dNTP, 1 × Mg free buffer and 1.5 mM MgCl2 in 
a final volume of 25 µl for 40 cycles using a thermal cycler (Hybaid Omni Gene System). 
The PCR reaction consisted of 35 cycles of denaturation at 94 °C for 30 seconds, primer 
annealing at 55°C for 30 seconds and DNA synthesis at 72°C for 30 seconds. RT-PCR 
products were separated by electrophoresis through 1.2 % of agarose gels that contained 
0.5 µg/ml ethidium bromide. Control PCR assays were performed in the absence of 
reverse transcriptase to confirm the absence of genomic DNA contamination in the total 
RNA sample. GAPDH was amplified for 30, 35, 40 cycles and analyzed to ensure the 
reaction was performed in the lineal stage.   
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To further understand the TNF-α mRNA expression in murine bladders after 1 and 6 
transfections and 1 month after the 6th transfection with liposome mediated- TNF-α, the 
transfected bladders were harvested to extract mRNA and performed RT-PCR.  All the 
mice were orthotopically implanted tumor into bladder 2 days before in vivo transfection 
to mimic the clinical application. Total RNA was isolated from 12 murine bladders using 
TRIzol according to the manufacturer’s instructions. RT-PCR was done as mentioned 
above. 
 
2.2.10 Orthotopic bladder cancer model  
 
Female C57BL/6 mice (4-6 weeks) were purchased and used to produce an orthotopic 
bladder cancer model. Single cell suspensions were prepared from 50-60% confluence 
MB49 cells and adjusted to a concentration of 1 × 10 6 cells/ml in blank RPMI 1640 
medium. The mice were anaesthetized and secured on a grounded plate with back fur 
shaved, and then catheterized with a 24-gauge plastic i.v. catheter through the urethra. A 
wire electrode was put into the bladder through the catheter. After a single transurethral 
cauterization at 0.2 watts to damage the bladder epithelium using monopolar coagulation 
function, (Aaron 800 high frequency desiccator, Aaron Medical Industries, INC. USA), 
100ul of above mentioned cell suspension was immediately instilled into the bladder via 





2.2.11 In vivo experiment with orthotopic bladder cancer model 
 
Twelve mice were randomized into two groups, pBud-TNF-α group and pBud control 
group. Each group had six mice. The treatment was started on the day 3 after tumor 
implantation. Plasmid-liposome mixture was prepared using the same protocol as in vitro. 
After anesthesia, 100 µl of this mixture was instilled into each bladder. The instillations 
were conducted twice a week. The animals were inspected daily for the signs of toxicity 
caused by TNF-α, and the signs of excessive tumor burden. The mice were weighed 
twice every week. On day 27, 5 days after the sixth instillation, bladders were harvested 
and weighed. The kidneys and lungs were checked for the presence of metastasis or any 
other abnormalities. The abnormal organs were removed and fixed in 10% buffered 
formalin for the further H&E staining and histological study. This experiment was 
repeated once. 
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Figure 2.1 Materials and methods used in producing murine orthotopic bladder cancer 
model. (A): a female C57BL/6 mouse (4-6 weeks) used in this study, (B): a wire 
electrode to cauterize the mouse bladder, (C): Aaron 800 high frequency desiccator, (D):  
A mouse was anaesthetized and secured on a grounded plate with back fur shaved. (E): A 
mouse was catheterized with a 24-gauge plastic i.v. catheter through the urethra. (F): The 
wire electrode was put into the bladder through the catheter. (G): 100ul of MB49 cells (1 
× 10 6 cells/ml) was instilled into the bladder after cauterization. 
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2.2.12 H&E staining  
 
Following fixation in 10% buffered formalin, all tissue were paraffin-embedded, serially 
sectioned (5µM) and stained with hematoxylin and eosin. Briefly, the dry paraffin 
sections were stained in following procedure:  
1. Pure xylene (5 minutes×2) 
2.50%xylene&50%alcohol (2 minutes)  
3.100% alcohol (5 minutes)  
4.100% alcohol (5 minutes)  
5.95% alcohol (5 minutes) 
6.70% alcohol (5 minutes) 
7. Tap water (2 minutes) 
8. Hematoxylin (20-90 second) 
9. Tap water (5 minutes) 
10. Acid alcohol (5 dips) 
11. Tap water (2 minutes) 
12. Eosin (2-3 dips) 
13. Tap water (2 minutes) 
14. 70% alcohol (5 minutes) 
15. 95% alcohol (5 minutes) 
16. 100% alcohol (5 minutes) 
17. Pure xylene (5 minutes×2) 
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The air-dry stained sections were then mounted by mounting medium. All the serial 
sections were examined carefully for the presence of the tumors. 
 
2.2.13 Immune cells infiltration into bladder after TNF-α therapy 
 
Four mice were orthotopically implanted bladder cancer and randomized into 2 groups. 
Two days after implantation, one group was transfected with pBud-TNF-α and another 
group was treated with pBud control vector. The intravesical instillation was carried out 
twice weekly. Two days after the third instillation, the mice were terminated and the 
bladders were harvested and rinsed with 1×PBS. The bladders were minced in 1 ml of 
blank RPMI 1640 and smashed with the plunge from 1ml syringe. Thereafter, the cells 
were filtered through a 40µm filter and centrifuged at 7K for 1 minute. The cell pellet 
was resuspended in 0.1% formaldehyde containing 10% of BSA and 0.01% azide and 
fixed for 1 hour. The fixed cells were then stained by 2µl of FITC anti-mouse CD3 and 
2µl of PE anti-mouse CD4 or 2µl of FITC anti-mouse CD3 and 2µl of PE anti-mouse 
CD8a or 2µl of FITC anti-mouse CD3 and 2µl of PE anti-mouse NK cells/2B4 (BD 
PharMingen,USA) in a total volume of 100µl overnight. The stained cells were sorted by 
flow cytometry and the flow data was analyzed by WinMDI 3.0.   
 
2.2.14 Statistical analysis 
 
Data was analyzed using SPSS 11.0. Independent-samples T test was used to compare the 
means of two groups. ANOVA was used to compare the means of three groups. 
 52
CHARPTER THREE                           RESULTS         
          
3.1 In vitro transfection optimization using reporter gene pCMVlacZ 
 
Since the general practice in clinics is to keep intravesical drugs in the bladder for up to 2 
hours after intravesical instillation, 2 hours of incubation time with MB49 cells after 
adding liposome-plasmid DNA lipoplex in vitro was used in this study. To optimize the 
plasmid DNA quantity used in this protocol, different amounts of pCMVlacZ gene were 
used to transfect MB49 cells. X-gal staining and ONPG assays were performed on the 
cells 48 hours after transfection.  
 
X-gal staining showed that among various amount of plasmid DNA, namely 0.5µg, 
2.5µg, 5µg, 7.5µg and 10µg of pCMVlacZ, 2.5µg gave the most cells with blue color, 
which is the indicator of transfection by reporter gene LacZ (Fig 3.1). Control cells which 
were transfected with 0µg of pCMVlacZ had no blue colonies. Similar results were 
obtained by using the reporter gene pBudCE.4.1/LacZ/CAT. Using 2.5µg of pCMVLacZ, 
the blue cells account for 30-40% of the total cell number after X-gal staining.  
 
To confirm the optimal plasmid DNA quantity required for the transfection observed by 
X-gal staining, β-galactosidase activity was determined by the ONPG assay 48 hour after 
pCMVLacZ transfection. The results showed that the OD at 420nm of 2.5µg pCMVLacZ 
was much higher than that of other amounts of pCMVLacZ (Figure 3.2). Hence 2.5µg of 
plasmid DNA was used to transfect target cells in the subsequent experiments. 
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Figure 3.1 X-gal staining of MB49 cells 48 hours after transfection with different 
amounts of pCMVLacZ   A: 0.5µg, B: 2.5µg, C: 5µg, D: 7.5µg, E: 10µg. 
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Figure 3.2: ONPG assay of MB49 cells which were transfected with different amounts of 
pCMVLacZ.  MB49 cells were transfected with 0-10 µg of pCMVLacZ and harvested 48 
hours after transfection. The ONPG assay was then carried out to determined 
galactosidase activity of the MB49 cells. 
 
3. 2. Construction and cloning of mouse TNF-α encoding plasmid 
 
The TNF-α cDNA was inserted into the multiple cloning site of pBudCE4.1 and its 
expression was driven by a pCMV promoter (Figure 3.3). The presence and orientation of 
TNF-α cDNA was checked by Sac I digestion and confirmed by automated sequencing 
(both forward and reverse). The alignment between the sequencing results and the TNF-α 
cDNA sequence in Genebank was done and shown to have 100% identity (Blast 1 and 
Blast 2). 
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Blast 1: Query:Insert(forward), subject: gi54844 Mouse mRNA for tumor necrosis factor 
  
Query:                           122 cgccacatctccctccagaaaagacaccatgagcacagaaagcatgatccgcgacgtgga 181 
                                     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           129 cgccacatctccctccagaaaagacaccatgagcacagaaagcatgatccgcgacgtgga 188 
pot. mouse TNF prepeptide (aa -> 1                                M  S  T  E  S  M  I  R  D  V  E 
 
Query:                           182 actggcagaagaggcactcccccaaaagatggggggcttccagaactccaggcggtgcct 241 
                                     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           189 actggcagaagaggcactcccccaaaagatggggggcttccagaactccaggcggtgcct 248 
pot. mouse TNF prepeptide (aa -> 12    L  A  E  E  A  L  P  Q  K  M  G  G  F  Q  N  S  R  R  C  L 
 
Query:                           242 atgtctcagcctcttctcattcctgcttgtggcaggggccaccacgctcttctgtctact 301 
                                     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           249 atgtctcagcctcttctcattcctgcttgtggcaggggccaccacgctcttctgtctact 308 
pot. mouse TNF prepeptide (aa -> 32    C  L  S  L  F  S  F  L  L  V  A  G  A  T  T  L  F  C  L  L 
 
Query:                           302 gaacttcggggtgatcggtccccaaagggatgagaagttcccaaatggcctccctctcat 361 
                                     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           309 gaacttcggggtgatcggtccccaaagggatgagaagttcccaaatggcctccctctcat 368 
pot. mouse TNF prepeptide (aa -> 52    N  F  G  V  I  G  P  Q  R  D  E  K  F  P  N  G  L  P  L  I 
 
 Query:                           362 cagttctatggcccagaccctcacactcagatcatcttctcaaaattcgagtgacaagcc 421 
                                     |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           369 cagttctatggcccagaccctcacactcagatcatcttctcaaaattcgagtgacaagcc 428 
pot. mouse TNF prepeptide (aa -> 72    S  S  M  A  Q  T  L  T  L  R  S  S  S  Q  N  S  S  D  K  P 
 
 Query:                           422 tgtagcccacgtcgtagcaaaaccaccaagtggaggagcagctgggagtgggctgagcca 481 
                                     |||||||||||||||||| |||||||||||||||||||||||| ||||| |||||||||| 
Sbjct:                           429 tgtagcccacgtcgtagc-aaaccaccaagtggaggagcagct-ggagt-ggctgagcca 485 
pot. mouse TNF prepeptide (aa -> 92    V  A  H  V  V  A   N  H  Q  V  E  E  Q  L   E   W  L  S  Q 
 
Query:                           482 gcgcgccaacgccctcctgggcaacggcatggatctcaaagacaaccaactagtggtgcc 541 
                                     |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           486 gcgcgccaacgccctcctggccaacggcatggatctcaaagacaaccaactagtggtgcc 545 
pot. mouse TNF prepeptide (aa -> 111   R  A  N  A  L  L  A  N  G  M  D  L  K  D  N  Q  L  V  V  P 
 
Query:                           542 agccgatgggttgtactttgtctacttccangttctcttcaanggaaaangntggccccg 601 
                                     |||||||||||||||| ||||||||| ||| ||||||||||| ||| || | | |||||| 
Sbjct:                           546 agccgatgggttgtaccttgtctactcccaggttctcttcaagggacaaggct-gccccg 604 
pot. mouse TNF prepeptide (aa -> 131   A  D  G  L  Y  L  V  Y  S  Q  V  L  F  K  G  Q  G   C  P   
 
Query:                           602 actac-tgctcctcacccaca 621 
                                     ||||| ||||||||||||||| 
Sbjct:                           605 actacgtgctcctcacccaca 625 
pot. mouse TNF prepeptide (aa -> 150 D  Y  V  L  L  T  H   
 
                                                                                                                                                                                                                     56 
 
Blast 2: Query:Insert(reverse), subject: gi54844 Mouse mRNA for tumor necrosis factor 
  
Query:                           349  cccattcccttcacagagcaatgactccaaagtagacctgcccggactccgcaaagtcta 408 
                                      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           874  cccattcccttcacagagcaatgactccaaagtagacctgcccggactccgcaaagtcta 815 
pot. mouse TNF prepeptide (aa -> 220            ^^^ L  A  I  V  G  F  Y  V  Q  G  S  E  A  F  D  L 
 
Query:                           409  agtacttgggcagattgacctcagcgctgagttggtcccccttctccagctggaagactc 468 
                                      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           814  agtacttgggcagattgacctcagcgctgagttggtcccccttctccagctggaagactc 755 
pot. mouse TNF prepeptide (aa -> 200    Y  K  P  L  N  V  E  A  S  L  Q  D  G  K  E  L  Q  F  V  G 
 
Query:                           469  ctcccaggtatatgggctcataccagggtttgagctcagccccctcaggggtgtccttgg 528 
                                      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           754  ctcccaggtatatgggctcataccagggtttgagctcagccccctcaggggtgtccttgg 695 
pot. mouse TNF prepeptide (aa -> 180    G  L  Y  I  P  E  Y  W  P  K  L  E  A  G  E  P  T  D  K  P 
 
Query:                           529  ggcaggggctcttgacggcagagaggaggttgactttctcctggtatgagatagcaaatc 588 
                                      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           694  ggcaggggctcttgacggcagagaggaggttgactttctcctggtatgagatagcaaatc 635 
pot. mouse TNF prepeptide (aa -> 160    C  P  S  K  V  A  S  L  L  N  V  K  E  Q  Y  S  I  A  F  R 
 
Query:                           589  ggctgacggtgtgggtgaggagcacgtagtcggggcagccttgtcccttgaagagaacct 648 
                                      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           634  ggctgacggtgtgggtgaggagcacgtagtcggggcagccttgtcccttgaagagaacct 575 
pot. mouse TNF prepeptide (aa -> 140    S  V  T  H  T  L  L  V  Y  D  P  C  G  Q  G  K  F  L  V  Q 
 
Query:                           649  gggagtagacaaggtacaacccatcggctggcaccactagttggttgtctttgagatcca 708 
                                      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:                           574  gggagtagacaaggtacaacccatcggctggcaccactagttggttgtctttgagatcca 515 
pot. mouse TNF prepeptide (aa -> 120    S  Y  V  L  Y  L  G  D  A  P  V  V  L  Q  N  D  K  L  D  M 
 
Query:                           709  tgccgttggccaagganggcgttggcgcgctggctcagccactccagctgctccctccac 768 
                                      ||||||||||| |||| ||||||||||||||||||||||||||||||||||| ||||||| 
Sbjct:                           514  tgccgttggcc-aggagggcgttggcgcgctggctcagccactccagctgct-cctccac 457 
pot. mouse TNF prepeptide (aa -> 117    G  N  A   L  L  A  N  A  R  Q  S  L  W  E  L  Q  E   E  V  
 
Query:                           769  ttggtggtttgcttcgacgtgggcttacaggcttgtcacttcgaattttga 819 
                                      ||||||||||||| |||||||||| |||||||||||||| ||||||||||| 
Sbjct:                           456  ttggtggtttgctacgacgtgggc-tacaggcttgtcac-tcgaattttga 408 






                                         
Figure 3.3: Map of the mammalian expression vector pBudCE4.1 
 
3. 3 In vitro TNF-α transfection and expression 
 
Endotoxin-free ultra-pure plasmid pBud-TNF-α was prepared for transfection after 
cloning. According to the optimal plasmid DNA quantity determined by LacZ gene, 
2.5µg of pBud-TNF-α was used to transfect 2x10 5 MB49 cells. About 893.7±24.0pg/ml 
of mouse TNF-α was detected by ELISA 48 hours after pBud-TNF-α transfection. TNF-
α was undetectable in parent cells or pBud transfected MB49 cells. These results showed 
that transfection with pBud-TNF-α using this non-viral delivery system leads to a high 
level of TNF-α protein expression in MB49 cells. 
 
3.4. Anti-proliferative activity after pBud-TNF-α transfection 
 
Two days after pBud-TNF-α transfection, the cells were counted to assess its anti-
proliferative activity. A significant inhibition of tumor proliferation was observed in 
pBud-TNF-α transfected cells (Fig. 3.4). The cell number at 48 hours after transfection 
was 55% (p<0.05) of that of parent cells or pBud transfected cells. This result suggests 
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that the TNF-α level expressed after transfection using our non-viral delivery system 









Figure 3.4: MB49 cell number of untransfected, pBud and pBud-TNF-α transfected cells 
48 hour after transfection. * indicates p<0.05 compared with untransfected cell and pBud 
transfected cell. 
 
3.5. In vitro killing of bladder cancer cell line with pBud-TNF-α 
 
3.5.1 Cell cycle analysis 
Cell cycle analysis of MB49 cells was performed 48 hours after transfection by PI 
staining (Fig 3.5). The percentage of cells in the G1 and G2 phases of the cell cycle in 
pBud-TNF-α transfected cells was lower than that of control cells. The sub-G1 cell 
population, which indicates the cells in late apoptosis (DNA fragmentation) was 
enhanced in TNF-α transfected cells in comparison with that of control cells (Table 3.1). 
This suggests that TNF-α transfection may directly induce bladder cancer cell apoptosis. 
 
 
















                              A                                                               B 
 
                          C 
    
Figure 3.5 PI staining results of parental cells (A), pBud (B) and pBud-TNF-α (C) 
transfected MB49 cells 48 hours after transfection. M1, M2, M3, M4 denotes cells which 
were in G1, S, G2 and sub- G1 phase respectively.  
 
Table 3.1: Cell cycle analysis of parental cells, pBud and pBud-TNF-α transfected cells 
 Sub G1 phase G1 Phase S Phase G2 Phase 
Parental cells   2.11 ± 1.45% 38.76±4.38% 11.28±3.24% 21.15±1.04% 
PBud   1.49 ± 0.74%     38.94±7.73% 11.42±1.54% 22.52±4.95% 
pBud- TNF-α   8.63 ± 0.53%     31.52±1.94% 13.22±0.26% 19.42±0.57% 
Data represent the Mean ± SD of three experiments done in duplicates  
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3.5.2 Annexin V staining 
To confirm the effect of inducing bladder cancer cell apoptosis after pBud-TNF-α 
transfection, Annexin-V staining, a sensitive test for identifying pre-apoptotic cells, was 
done 48 hours after transfection. Approximately 32% of the MB49 cells were induced to 
a pre-apoptotic state after transfection (Figure 3.6).  
 
 
Figure 3.6 Annexin-V staining of pBud (filled histogram) and pBud-TNF-α (open 
histogram) transfected cells 
 
 
Table 3.2 Annexin-V staining of parental cells, pBud and pBud-TNF-α transfected cells 
Plasmid  Percentage of positive cells after Annexin-
V staining 
Parental cells    ND 
Pbud    5.17 ± 0.08 
pBudTNF-α   32.10 ± 7.52 





3.6 Flow cytometric analysis for surface immuno-related molecules and Fas receptor 
 
Forty-eight hours after pBud-TNF-α transfection, MHC class I, MHC-class II, B7.1, ICAM I 
and Fas antibody stained cells were analyzed by FACS. It showed that MHC class I, B7.1 
and Fas molecule expression on MB49 cells were up-regulated after transfection 
compared with control cells (Table 3.3). There was no increase in MHC class II and 
ICAM I molecules on MB49 cells after treatment.  
 
Table 3.3 The expression level of MHC I, B7.1 molecules and Fas antigen on MB49 
cells 48 hours after pBud-TNF-α transfection 
 
                               Percentage of positive cells Plasmid  
MHC I B7.1 Fas 
None  15.46 ± 9.61 5.83 ± 1.76  11.05 ± 7.91 
pBud  13.04 ± 10.93  6.40 ± 2.19  16.43 ± 11.59  
pBud-TNF-α  62.73 ± 11.83 34.73 ± 11.43  48.40 ± 18.95 
 
Data represents the Mean ± SD from five experiments. 
 
 
3.7 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) analysis of TNF-α 
expression in vivo 
 
Next, we checked the transfected gene expression level in vivo after in situ direct TNF-α 
gene transfer to mouse bladder by measuring the cytokine protein in the mouse urine. The 
mouse urine was collected after the first, third and sixth intravesical instillation of pBud-
TNF-α. TNF-α protein level in urine was determined by ELISA.  It showed negative 
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results in all urine samples from the transfected mice. We then switched to detect TNF-α 
expression in vivo by monitoring the mRNA level of TNF-α. 
 
RT-PCR was performed using mRNA extracted from pBud-TNF-α and pBud transfected 
mouse bladders which have no tumor implanted. It showed TNF-α mRNA was readily 
detectable in pBud-TNF-α transfected mouse bladder 2 days after transfection. In 
contrast, it was undectable in pBud control vector transfected mouse bladder (Figure 
3.7.1). This suggests that intravesical administration of the therapeutic gene with our 
novel liposome system is able to deliver the therapeutic gene to the target organ and get 
the gene expressed successfully. Using LacZ gene, we also demonstrated that this 
strategy is safe because the marker gene can only be found in bladder, but not in liver, 
kidney, heart, brain, lung or ovary. 
 
                                                          1           2            3            4   
 
                               TNF-α 
 
                               GAPDH 
Figure 3.7.1 RT-PCR results after in vivo direct TNF-α gene transfer to mouse bladders 
(non-tumor implanted bladders). TNF-α mRNA expression level were determined by RT-
PCR. GAPDH was amplified as control. lane 1&2: mRNA from control vector 
transfected mouse bladder, lane3&4: mRNA from TNF-a transfected mouse bladder, 
lane1&3: PCR with RT, lane 2&4: PCR without RT. 
 
 
To monitor TNF-α mRNA expression in murine bladders after 1 and 6 transfections and 
1 month after the 6th transfection, RNA was extracted from the transfected bladders and 
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RT-PCR was performed.  All the mice had been orthotopically implanted with tumor 
cells 2 days before in vivo transfection to mimic the clinical application. The results 
showed that after 1 instillation with pBud-TNF-α, the TNF-α mRNA in bladders was 
enhanced significantly compared with that of the control vector transfected bladders (lane 
4-6 compared to lane1-3, Fig 3.7.2). After 6 instillations, the TNF-α transcription was 
further increased and then returned to the level of control vector transfected bladders 1 
month after the last transfection (lane 7-9 compared to lane10-12, Fig 3.7.2).       
 
                                                                              (a)                                                                                            
                                         1     2     3     4     5      6      7     8      9     10   11    12   
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bladders (1 month after
the 6th instillation)






Fig 3.7.2. RT-PCR results after treatment using murine orthotopic bladder cancer model. 
(a) shows a representative mRNA expression of TNF-α after intravesical treatment in 
tumor implanted mouse bladders. lane 1-3: mRNA from control vector transfected mouse 
bladder (2 days after 1 instillation), lane 4-6: mRNA from TNF-α transfected mouse 
bladder (2 days after 1 instillation), lane 7-9: mRNA from TNF-α transfected mouse 
bladder (2 days after 6 instillations), lane 10-12: mRNA from TNF-α transfected mouse 




3.8 Murine orthotopic bladder cancer model 
 
To reflect the biology of human bladder cancer as it presents in the clinics, a murine 
orthotopic bladder cancer model was developed in our lab. MB49 cells were 
intravesically instilled to the bladder of syngeneic mouse strain C57BL/6 after a single 
transurethral cautery at 0.2 watts to damage the bladder epithelium. A single tumor 
formed in bladder in 1 week (Figure 3.8). Histological study of the tumor showed it was 
transitional cell carcinoma (TCC) and the xenografts grew as superficial tumors with no 
evidence of invasion (Figure 3.9). 
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Figure3.8:  Murine orthotopic bladder cancer model. A: The left mouse has tumor 
implanted in bladder while the right one is a control mouse with normal bladder. B: The 
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Figure 3.9: Histological study of mouse bladder (H&E staining). A&C: 4×10 
magnification, B&D: 10×10 magnification) A&B: C57BL/6 mouse bladder which is 
instilled with MB49 cells after damaging the epithelium presents with a transitional cell 
carcinoma in bladder. The tumor does not invade muscle layer.  C&D: The architecture 
of a normal C57BL/6 mouse bladder. 
 67
3.9 Tumor growth suppression of pBud-TNF-α in vivo 
 
We then evaluated the effect of TNF-α gene on suppressing the growth of established 
bladder cancer in vivo using the orthotopic bladder cancer model mentioned above. The 
treatment was started 2 days after tumor implantation. Six intravesical instillations of 
liposome-mediated pBud-TNF-α were performed in total, i.e. twice weekly. All the mice 
(n=24) had severe hematuria 1-2 weeks after tumor implantation. Three mice died in the 
control group (n=12) while only 1 mouse died in pBud-TNF-α treated group (n=12). The 
remaining mice were terminated 5 days after the sixth instillation, namely day 27 after 
tumor implantation. Treatment with the TNF-α gene was well tolerated. No treatment-
related death and adverse effects, such as diarrhea, rigor and weight loss were observed in 
the pBud-TNF-α group. The cured animals continually gained weight while some non-
cured animals lost weight because of their tumor burden. 
 
Necropsy showed that all the mice that died before the termination died from excessive 
bladder tumor burden. The average bladder weight of mice in the pBud-TNF-α treated 
group is 44.1% lower than that of the control group while the average body weight of 
mice in pBud-TNF-α group is 20.7 % higher than that of the control group. There was a 
significant difference in the relative organ weight (ROW) between the pBud-TNF-α 
treated group and control group (p<0.05) (Table 3.4).  No metastasis was found in liver, 
heart, lung, intestine and bone. No hepatosplenomegaly was found in all the mice. Two 
mice had unilateral kidney enlargement and 2 mice had bilateral kidneys enlargement in 
the pBud control group while only 1 mouse in the pBud-TNF-α group had bilateral 
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kidney enlargement. All the abnormal kidneys were removed for the pathological study. 
All the bladders were removed and serially sectioned to exam the presence of tumors. 
 
Table 3.4 Body and bladder weights of mice with orthotopic bladder cancer given 
intravesical TNF-α gene therapy.  
 
                      Bladder Weight Group     
(n=10)               
     Body     
Weight (g)                    (g)                    ROW          
pBud 14.5± 0.9           0.059±0.0093       45.17±10.01 
pBud-TNFα      17.5± 0.4           0.033±0.0050       18.91± 3.18 
 
Data represents the mean ± SEM for bladder weight and ROW (relative organ weight). 
ROW= [organ weight (g) × 10 4 ]/Body weight (g). There is a significant difference in 
ROW between pBud-TNF-α and pBud group (p=0.03). (Two bladders in each group 
were randomly selected and distended by formalin before termination and therefore 
excluded from calculation) 
 
Histological study showed that 9 of 12 mice in the control group had tumors in the 
bladder. In contrast, only 3 of 12 animals in the pBud-TNF-α treated group were 
demonstrated to have bladder cancer (Table 3.5& Fig 3.10). No renal metastasis was 
found in any of the mice. The enlargement of the kidney was caused by hydronephrosis. 
Four of 12 mice in the control group had hydronephrosis while only 1 of 12 mice in the 
pBud-TNF-α treated group had the same problem.  
 
Table 3.5 Histological study of mouse bladder and kidney in intravesical TNF-α gene 
therapy. 
 
Group  (n=12) No. with bladder tumor No. with hydronephrosis 
pBud 9/12 (75%)  4/12 
pBud-TNF-α 3/12 (25%) 1/12 
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Figure 3.10: H&E staining of mouse bladder after treatment. (A&B: Magnification: 4×10, 
C&D: Magnification: 10×10) A&C: A tumor implanted bladder, after 6 instillation of 
pBud-TNF-α, shows normal epithelium. B&D: A tumor implanted bladder treated with 






3.10 Immune cells infiltration into bladder after TNF-α therapy 
 
To check whether direct TNF-α gene transfer to bladder can boost the host immune 
system by attracting the immune cells infiltration into the bladder, the mouse bladder was 
removed, minced and resuspended in RPMI 1640 2 days after the third instillation. The 
cells were stained with CD3, CD4, CD8 and NK monoclonal antibody and analyzed by 
flow cytometry. The results showed that the T lymphocytes and NK cells in bladder were 
enhanced after intravesical instillation of liposome mediated TNF-α. 
 
Figure: 3.6 CD3, CD4, CD8 and NK positive cells in pBud-TNF-α and pBud transfected 
bladders.  
                                                                                                                                                                
Immune cell marker pBud (n=2) pBud-TNF-α (n=2) 
CD3 30.63±1.63% 48.28±4.87% 
CD4 20.65±1.53% 24.50±0.10% 
CD3 CD4 16.98±1.19% 21.00±0.11% 
CD8 20.24±4.46% 22.55±6.51% 
CD3 CD8 15.56±2.21% 19.96±4.78% 
NK 20.96±2.84% 26.77±2.82% 
CD3 NK 16.74±2.44% 23.48±0.72% 







CHARPER FOUR                             DISCUSSION 
 
In this study, a novel cationic liposome mixture composed of DOTAP plus MBC was 
used to deliver the therapeutic gene. We demonstrated this non-viral system was efficient 
in delivering target genes to bladder cancer cells in vitro as well as bladder cancer tissues 
in viv. This is evidenced by the moderate amount of mouse TNF-α expressed in the 
supernatant and the detectable band in RT-PCR. Although TNF-α protein was 
undetectable in the urine after the first, third and sixth intravesical instillation of pBud-
TNF-α, we speculate that several reasons may account for the results, such as the 
stability of TNF-α protein in urine, the amount of TNF-α protein which can be 
accumulated in the urine and the possibility of the denaturation of TNF-α protein in the 
salts or other compounds of the urine. The TNF-α titer obtained from murine bladder 
cancer cell MB49 cells using our transfection system is not as high as that of some other 
studies using adenovirus vector (Marr et al., 1998; Kianmanesh et al., 2001). However, 
some facts should be taken into account when comparing our results with these results. 
 
First, cytokine titer expressed by the transduced cells is highly cell-type dependent. Marr 
et al transfected human fibroblast MRC5 (ATCC CCL-171) cells and murine melanoma 
B16BL6 cells with the same human TNF-α encoding adenovirus vectors (AD-HCMV-
TNF) under the same condition. The TNF-α titer from MRC5 was greater than 3000 
ng/106 cells on day 6 after transfection, which was 1000 time higher than that from B16 
cells on day 6 (Marr et al., 1998). A similar phenomenon was observed in other studies. 
Hu et al transfected a human bladder carcinoma cell line 5637 and prostate carcinoma 
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cell line LNCa.FGC with a tetracycline-regulatable recombinant adenovirus vector 
encoding TNF-α. The TNF-α produced by 5637 cells (6000 pg/106cell/24 hours) was 
more than 15 times higher than that obtained from LNCa.FGC cells (400 pg/106 cell/ 
24hours) (Hu et al., 1997).  
 
Secondly, it is expected that the TNF-α titer obtained using our non-viral gene deliver 
system would be lower than that obtained from adenovirus vectors because adenoviruses 
are well known to have very high transfection efficiencies in many cell lines. However, 
for a potent cytokine like TNF-α, too high a titer of protein product can also cause severe 
side-effects, even with local administration. Kianmanesh et al used adenovirus vector 
encoding TNF-α to transfect CT26 colon carcinoma. The titer of TNF-α in the 
supernatant was as high as 700-800 ng/ml 72 hours after transfection. Severe toxicities 
including significant weight loss and diarrhea (3/3) and treatment related death (1/3) were 
observed after intratumoral injection of this adenovirus vector into a subcutaneous model 
of colon cancer (Kianmanesh et al., 2001). Considering that man can only tolerate 2% of 
the dose/kilogram which is essential to obtain tumor regression in mice when TNF-α is 
admininstered systemically (Sidhu et al., 1993), special care should be taken to avoid too 
high titer of TNF-α which may enter into the circulation via local microvasculature even 
though it is applied locally.  Moreover, lower concentrations of TNF-α do not necessarily 
mean lower inhibitory effects on tumor cells. Adenovirus mediated TNF-α transduced 
prostate carcinoma cells LNCaP.FGC secrete only moderate amounts of TNF-α (~400 
pg/10 6  cell/ 24hours), at which level, however, the majority of the transduced 
LNCaP.FGC cells will die (Hu et al., 1997). 
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Thirdly, although viral vectors including adenovirus, retrovirus, and herpes-simplex virus 
are more commonly used in cancer gene therapy and may have higher transfection 
efficiency, these vectors also have their own limitations. Retroviruses may cause 
insertional mutagenesis because of random integration into the host genome. Recently, it 
was reported that a child participating in a gene therapy trial using retrovirus had 
developed leukaemia (Gore, 2003).  Adenoviruses are strongly immunogenic. 
Furthermore, it has been shown that the expression of the human coxsackie and 
adenovirus receptor (hCAR), which is regarded essential for adenovirus to enter into 
target cells, was variable amongst different human bladder cancer cells (Li Y, et al., 
1999). This raises the question of the feasibility of adenovirus-mediated gene therapy for 
bladder cancer. However, more recently, another study found that although 
immunohistochemistry results using a monoclonal antibody against hCAR showed 
homogeneous expression of the receptor throughout the full thickness of the urothelium, 
only the superficial layers were infected by the adenovirus while the monolayer cells 
derived from the same pieces of tissue and the same patients can be transfected by the 
adenovirus with much higher efficiency.  Thus the authors argued that it is a physical 
barrier, most likely the multilayered structure of intact urothelium, rather than hCAR 
status that may be the main determinant of the transduction efficiency of the intact 
epithelium (Chester et al., 2003).   In contrast, no receptors are required for cationic 
liposome-mediated gene delivery.  Furthermore, liposome-mediated gene delivery in vivo 
has been demonstrated to be safe in various animal studies and is being evaluated in a 
number of clinical trials.  Successful gene transfer to the target tissues and the expression 
of the transduced gene of interest were achieved without any complications. When 
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compared with retroviral transfection, multiple copies of the plasmid can be transduced 
per cell leading to higher production of the transduced gene of interest for a shorter 
period of time. Since the mechanism of transfection is not based on genomic integration, 
gene expression is transient. However, if gene expression persists long enough for 
significant immuno-modulation, the transient nature of transfection becomes less 
important in bladder cancer. The ease of repeated intravesical instillation may 
compensate for the lower transfection efficiency of liposomes.  
 
Mature tumor necrosis factor α (TNF-α) is a 17 kD polypeptide that binds to two cell 
surface receptors p55 and p75 (Asher et al., 1987). This proinflammatory cytokine has a 
variety of physiological effects including potent experimental antitumor activity. TNF-α 
was reported to exert its antitumor effects in three ways. The first is through direct 
cytotoxicity to tumor cells, by inducing apoptosis through engagement of the p55 TNF 
receptor (Fiers, 1991). The second mechanism is through the activation of immune cells 
like T cells, NK cells, macrophages as well as inducing cytokines like IL-6, GM-CSF, IL-
8, etc (Tracey et al., 1994; Paleolog et al., 1994). The third mechanism is through its 
selective action on the neovasculature in the tumor microenvironment, leading to 
intravascular thrombosis within tumor and thereafter ischemic necrosis (Scheurich et al., 
1987; Ranges et al., 1987).  
 
TNF-α is believed to make an important contribution to the efficacy of BCG therapy of 
bladder cancer (Shin et al., 1995; Jackon et al., 1995; Balbay et al., 1994). Studies have 
shown that among the constituents of the urinary “cytokine soup” induced by intravesical 
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BCG, namely TNF-α, interferon-γ, interleukin-1 and interleukin-2 (Bohle et al., 1990; 
Prescott et al., 1990; Haaff et al., 1996), TNF-α and interferon-γ were the only cytokines 
which demonstrated significant anti-proliferative effects on the bladder cancer cells 
(Hawkyard et al., 1993). Furthermore, the data in laboratory and clinical studies also 
demonstrated its effectiveness in inhibiting bladder cancer. (Niell et al., 1994; Serretta et 
al., 1995; Lee et al., 1987; Kadhim et al., 1988; Sternberg et al., 1992; Glazier et al., 
1995).  The major problem which limits the clinical application of TNF-α in cancer 
treatments is the severe toxicity associated with systemic administration, such as sepsis-
like syndrome, shock, hypotension, confusion, malaise, confusion, headache, rigors, 
fever, chills, diarrhea, lethargy, vomiting, hepatosplenomegaly, leukothrombopenia, 
anorexia, cachexia and weight loss (Chapman et al., 1987; Feinberg et al. 1988). 
Although intravesical immunotherapy of recombinant TNF-α shows good tolerance and 
little side-effect in patients, the response rate was inferior to BCG therapy. Part of the 
reason for this may be attributed to the limited retention time of TNF-α in bladder and 
the lack of the post-translation modification processes of recombinant TNF-α.  Direct 
TNF-α gene transfer to bladder cancer cell may not only circumvent the problems 
encountered following systemic administration by providing high titers of cytokine in the 
vicinity of the tumor cell and lead to tumor suppression, but also solve the problems like 
rapid degradation and the short half life after administration of the recombinant TNF-α. 
Moreover, it has also been reported that endogenously TNF-α produced by the 
transfected tumor cells may promote the expression and secretion of further factors 
capable of synergizing with TNF-α to induce apoptosis at cytokine levels over 100-fold 
less than those required to achieve the same effect with exogenous added TNF-α (Gillio et 
 76
al., 1996). All these facts encouraged us to test the hypothesis that intravesical TNF-α 
gene therapy is effective to treat bladder cancer.  
 
Our study showed that 75% of tumor implanted mice (9 of 12) which were treated with 
liposome mediated TNF-α gene were tumor-free while only 25% (3 of 12) of mice which 
were treated with pBud control vector had no tumors in the bladder. All the TNF-α 
treated mice were normal. No diarrhea and no treatment-related deaths were observed. 
The cured animals continually gained weight while non-cured animals lost weight 
because of their tumor burden. This results support the hypothesis that in situ cytokine 
gene transfer to bladder can achieve an anti-tumor effect with less risk of systemic effect. 
Kianmanesh et al showed that a single intratumoral injection of high dose (10 9 pfu) of 
TNF-α encoding adenovirus vector can completely suppress tumor growth in murine 
subcutaneous colon cancer model (3/3) and melanoma model (5/5). Unfortunately, this 
effect was also associated with severe toxicities including significant weight loss and 
diarrhea (3/3 in colon cancer, 3/5 in melanoma) and treatment related death (1/3 in colon 
cancer, 1/5 in melanoma). Two factors may account for the difference between this study 
and ours. Firstly, intratumoral injection which was applied in Kianmanesh’s study may 
have resulted in systemic transfection of the TNF-α gene via the tumour vasculature, a 
problem that is rare with intravesical drug administration. Secondly, the large amount of 
adenoviruses vectors (10 9 pfu) used in this study and higher transfection efficiencies of 
adenoviruses may result in a much higher amount of TNF-α being produced in vivo with 
a concomitant increase in side-effects. Their study reported that 72 hours after 
transfection at a multiplicity of infection (MOI) of 70 there was >700ng/ml of TNF-α 
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produced in vitro which is 1000 fold more than that produced by our transfection system. 
This may also explain the reason that we did not achieve their cure rate of 100%. At a 
lower dose of 107 PFU adenovirus only partial suppression of the tumor (45% of 
suppression 2 weeks after vector administration) was observed. But there was no data as 
to how much TNF-α was produced by this dose of virus in vitro. In their study tumor 
reduction was solely dependant on an intact immune system.  
 
In our animal study, 25% of the mice in the control group were tumor-free, indicating an 
implantation success rate of 75%. This rate is comparable with other orthotopic bladder 
cancer model studies using cauterization which showed a tumor incidence of 38-84% 
(Bonfil et al., 1997; Soloway et al., 1983; See et al., 1987). Unlike the bladder tumors 
induced by chemical carcinogens such as N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide 
(Ibrahiem et al., 1983) and N-methyl-N-nitrosourea (NMU) (Elsasser-Beile et al., 2001) 
or created by applying corrosive chemicals like hydrochloric acid (HCL) and potassium 
hydroxide (KOH) followed by tumor cell instillation (Xiao et al., 1999; Chin et al., 
1991), the bladder tumors formed using our technique are unifocal, superficial, papillary 
and have predictable location. These tumors resemble bladder cancers that occur in the 
clinics, both anatomically and histologically. Therefore this orthotopic tumor model is 
suitable for the evaluation of the treatment strategies of bladder cancer. 
 
Our study showed at least two pathways might be involved in the anti-tumor effect of 
TNF-α gene transfection. The first is the direct effect of inducing apoptosis. This effect 
was shown by PI staining, which discriminates between hypodiploid DNA and diploid 
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DNA. It revealed the presence of an apoptotic peak 48 hours after pBud-TNF-α 
transfection. The effect was then confirmed by Annexin V staining, an indicator of the 
early stage of apoptosis. It demonstrated that as many as 35.4% of the MB49 cells were 
stained by Annexin V 48 hours after pBud-TNF-α transfection. Although PI staining 
showed only 6.3% pre-G1 cells, this may be because the 48 hour duration was not 
sufficient for MB49 cells to have DNA fragmentation under these circumstances. The 
direct apoptotic effect of TNF-α is consistent with another study which demonstrated that 
the transfer of the TNF-α gene into lymphoma T-cell can restore the physiologic cell 
death program lost by neoplastic cells (Gillio et al., 1996). Since it has been previously 
demonstrated that the expression of APO-1/Fas is up-regulated by exposure to either 
IFN-γ and/or TNF (Watanabe-Fukunaga R et al., 1992; Weller et al., 1994; Fellenberg et 
al., 1997), we then furthered our experiments by investigating the expression level of Fas 
receptor on the surface of MB49 cells after TNF-α gene transfection. This showed that 
APO-1/Fas receptor, a member of TNF/NGF receptor superfamily, was enhanced 
significantly after TNF-α transfection. As APO-1/Fas mediates apoptosis when it is 
cross-linked with Fas ligand on activated T cells and NK cells, we speculate that 
Fas/FasL may also play a role in the apoptotic effect in vivo after TNF-α transfection.  
Lee et al also demonstrated that the overexpressed Fas provides a functional target in vivo 
for T lymphocyte cells and results in the delay of in vivo tumor progression (Lee et al., 
2000). 
 
A more important mechanism is the stimulation of T-cell-mediated immunity to the 
tumor, which is critical to convert the immunological silence around the tumor cells. In 
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our study, we found a considerable increase in MHC I and B7-1 expression after TNF-α 
transfection. This event is crucial in activating tumor specific CD8 +  TCL considering 
that MHC I and co-stimulatory molecules such as B7-1 and B7-2 are the two essential 
signals in the activation and effector function of CD8 +  cytotoxic T lymphocytes (CTLs) 
and the responding T lymphocytes would be “anergized” or “tolerized” rather than 
activated if MHC I positive tumor cells presents tumor antigen in the absence of a co-
stimulatory signal (George et al., 1989; Browning et al., 1992; Linsley et al., 1993; 
Townsend et al., 1993; Darnell  et al., 1994;). Therefore, the up-regulation of these two 
molecules could significantly enhance the T cell mediated immune response which may 
be closely related to anti-tumor effect. As expected, MHC II expression was not found to 
be enhanced after TNF-α transfection. A similar result was reported elsewhere (Jackson 
et al., 1993). Nevertheless, Hawkyard et al showed that although TNF-α could not induce 
the expression of MHC II antigen from the cells which were initially MHC II-negative, it 
enhanced the expression on cells which already demonstrated a low level of the antigen 
(Hawkyard et al., 1993). In an analysis of 37 bladder tumors Nouri and Symes reported 
that about 54% were negative and the remaining had either strong or weak MHC class II 
expression (Nouri et al., 2000).   Therefore, it is possible that when human bladder cancer 
which expresses low level of MHC II is transfected with pBud-TNF-α, MHC II 
expression may be enhanced, leading to the co-activation of CD4 + tumor specific 
lymphocyte and a more potent anti-tumor immunity (Kern et al., 1986). The effect of the 
stimulation of T-cell-mediated immunity to the tumor after direct TNF-α gene transfer to 
tumor cells was further demonstrated by our in vivo study. It showed that CD3 + , CD4 + , 
CD8 +  and NK +  cells in mouse bladders are significantly enhanced 2 days after the third 
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instillation of liposome mediated TNF-α gene. These results suggest that T lymphocytes 
and NK cells are also involved in the anti-tumor effects of TNF-α, providing the in vivo 
evidence of immune activation after in situ TNF-α gene transfection. 
 
TNF-α has been reported to induce transformation of a normal rat urothelial cell line 
after 1 week of exposure at a concentration of 10ng/ml (Okamoto et al., 1997). This 
amount of TNF-α was at least 10-fold more than that produced by our transfection. Thus 
the likelihood that TNF-α could be detrimental in bladder cancer therapy is low. 
However, to confirm this, the long-term effect on mice of 6 intravesical instillations of 
TNF-α will need to be examined. 
 
                                                  












CHARPTER FIVE    CONCLUSIONS AND FUTHER DIRECTIONS 
 
In summary, our intravesical gene therapy using TNF-α as a therapeutic gene shows 
intravesical instillation of liposome mediated TNF-α gene can produce sufficient TNF-α 
protein in the vicinity of the bladder cancer cells to significantly inhibit their growth 
without any severe side-effects which have been observed in the approach of intratumoral 
injection of viral vector mediated TNF-α gene. It demonstrates that intravesical 
administration of therapeutic genes is a feasible and efficient in situ gene transfer 
approach for bladder cancer. Two mechanisms including direct apoptotic effect against 
bladder cancer cell and the activation of immune cells to tumor were shown to be 
involved in the antitumor activity of TNF-α gene therapy.  
 
These results suggest that intravesical cytokine gene therapy may be useful as an 
adjuvant therapy for bladder cancer. Superficial bladder cancer patients who have 
undergone TURBt and patients with carcinoma-in-situ bladder cancer have low tumor 
burden but high risk of recurrence. They may benefit from this gene therapy strategy. It 
may be especially valuable for BCG-failures. Late stage invasive bladder cancer patients 
who have clinically unresectable tumors may also benefit from this strategy or through 
intratumoral injection of liposome mediated therapeutic cytokines.    
 
However, as far as this study is concerned, some improvements can still be made to give 
a more accurate evaluation of cytokine gene therapy. For example, a technique which 
allows the confirmation of the presence of orthotopic bladder tumor before starting the 
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treatment and also permits the monitoring of the growth of the tumor during the treatment 
would give more convincing evidence. To achieve this aim, Magnetic Resonance 
Imaging (MRI) of the growth of the bladder tumor, green fluorescent protein (GFP) 
transfected bladder cancer cells and prostate specific antigen (PSA) transfected bladder 
cancer cells which can be implanted into the mouse bladder to simplify the tumor 
estimation are being studied.  
 
Before a clinical trial can be initiated, more work should be done to refine our protocols. 
For instance, we may need to investigate whether six instillations are necessary to attain 
the optimal treatment effect or whether less would be as effective. Long-term observation 
after treatment may also be necessary to observe whether the cured mice would have 
recurrences or any side effects.  
 
To augment the efficacy of the cytokine gene therapy, several other genes such as IL-2, 
GM-CSF, Interferon-γ are being screened. GM-CSF was chosen to be co-cloned into 
pBudCE4.1 with TNF-α to construct a mammalian expression vector which contained 
both mouse TNF-α gene and mouse GM-CSF gene (pBud-TNF-GM-CSF). 
Unfortunately, no synergistic effect was observed both in vitro and in vivo when plasmid 
pBud-TNF-GM-CSF was transfered into bladder cancer cells. Other strategies like the 
combination of cytokine gene therapy with corrective gene therapy (such as wild type 
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